Podcasts about visus

In this episode John A. Hovanesian, MD, FACS, and Jim Mazzo are live from SightLine at the ASCRS meeting with guests Nicole R. Fram, MD, Kerry D. Solomon, MD, Vance Thompson, MD, and Steve Speares. Welcome to the Eyeluminaries podcast 00:02 Review of episode 32 00:55 Intro of Nicole Fram, MD 01:16 Tell us why the MAHRVELS team is likely to be the leading fundraisers and why you picked your character for the team to portray (The Scarlet Witch)? 02:24 Meeting about complications from cataract surgery, what do you think is the next big phase on how we're going to handle complications with technology? 04:05 Psychology of managing patients/conveying care 05:42 What advice do you give to people who are starting their career? 06:50 Intro of Kerry Solomon, MD 09:30 What do we often get wrong with cataract surgery and what do we often get right? 10:25 How do you stay an entrepreneur and a leading physician? 11:55 What is Operation Sight? How did you create it? 14:19 Where will keratorefractive surgery and lens-based surgery be in 5 or 10 years? 18:30 Intro of Vance Thompson, MD 21:24 What's it like to be ASCRS president? 21:59 What is BRiCS and why is it important? 23:54 You've created a culture; can you talk about that culture you've created at your institute? 29:30 Tell us about your winery! 33:28 Intro of Steve Speares 36:45 ASCRS just wrapped up. Your idea of creating a SightLine with a business approach, what did you do and what was the idea? 38:00 As you look back and you look ahead, what changes do you hope to make? What do you hope your legacy will be at ACSRS? 40:57 Can you expand more on how Washington, DC and Trump administration will impact your society/group? 44:19 Richard Lindstrom in ASCRS hall of fame, tell us your own perspective and a good story 46:29 Preview of episode 34 52:09 Give us your feedback 52:40 Thanks for listening 52:56 Nicole Fram, MD, is an adjunct assistant professor at the John A. Moran Eye Institute at the University of Utah. She is also the secretary for ASCRS, is a member of the Cataract Clinical Committee, and leads the Ophthalmology Quicksand Chronicles podcast with co-host Elizabeth Yeu, MD. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Kerry Solomon, MD, is internationally renowned for LASIK and refractive cataract surgery. He is the co-founder of Operation Sight. He is the former chairman of the ASCRS FDA Committee. Steve Speares, MD, is the executive director at ASCRS. Vance Thompson, MD, is the founder of Vance Thompson Vision and director of refractive surgery in Sioux Falls, SD. He serves as a professor of ophthalmology at the Sanford School of Medicine at the University of South Dakota. Thompson is the immediate past president of ASCRS. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Fram, Speares, Solomon, and Thompson at the time of publication.

Sodra skelbia, kad atnaujintos pensijos visiems dirbantiems pensininkams turi būti išmokėtos iki liepos pabaigos.Naujasis Popiežius į Šventąjį Sostą įžengs kitą sekmadienį po inauguracijos mišių. Kaip tam ruošiamasi?Putinui pasiūlius kitą savaitę Stambule surengti tiesiogines derybas su Ukraina, Paryžius sako, kad toks žingsnis nepakankamas.Kurių žydinčių augalų žiedadulkės sukelia gali sukelti alergines reakcijas?Laidos ved. Madona Lučkaitė

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news from Washington with guest Mark Leahey. Welcome to the Eyeluminaries podcast :02 Review of episode 31 :40 BVI Medical names a new CCO 2:20 GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions 5:42 Tenpoint submits new drug application for presbyopia combination therapy 7:33 Alcon acquires majority stake in Aurion Biotech 10:29 FDA approves Encelto for macular telangiectasia type 2 14:50 Intro of Mark Leahey 17:28 There is a lot of attention on the HHS restructuring. What are your insights into what has happened to date, and what could happen in the future? 20:10 What do you think about the leadership? 23:44 Let's talk about sustainability. Tell us about the medical device industry's collective interest and challenges in regard to moving toward environmentally sustainable initiatives. 24:59 Let's talk about leadership: Dr. Marty Makary and Dr. Oz. 27:53 Tariffs are an evolving subject. What is the impact on the medical community? What is your impression on how these will affect us in the short term and long term? 33:20 Preview of episode 33 39:27 Give us your feedback 40:23 Team Mah-rvel: the Party for a Purpose 40:41 Thanks 40:58 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Mark Leahey is the president and CEO for the Medical Device Manufacturers Association (MDMA). Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Leahey.

Stāsta senās mūzikas pētniece, multiinstrumentāliste, vēsturisko pūšaminstrumentu pārvaldītāja Ieva Nīmane Kad Mocarts ar ģimeni ieradās Vīnē, viņš iepazinās ar Antonu Štadleru – tolaik spožāko un ievērojamāko klarnetistu, kura spēli Mocarts apbrīnoja vēstulēs savam tēvam. Par Antona Štadlera spēli teikti šādi vārdi “Nekad neesmu dzirdējis ko līdzīgu tam, ko jūs spējat izpildīt uz sava instrumenta... Jūsu instrumenta tonis ir tik maigs, tik smalks, ka neviens, kam ir sirds, tam nespēj pretoties.” Klarnete tikai 18. gadsimta otrajā pusē sāka iekarot pastāvīgu vietu uz koncertskatuvēm un orķestra partitūrās, jo līdz tam šo instrumentu spēlēja orķestra obojisti vai fagotisti. Bet līdz ar pirmo solistu parādīšanos auga arī instrumenta prestižs un repertuārs. Pēc Mocarta un Štadlera satikšanās Vīnē 1781. gadā visās Mocarta operu partitūrās parādās klarnetes. Nozīmīgākie Mocarta darbi šim instrumentam, tādi kā  Klarnetes kvintets Lamažorā K.581 un arī Koncerts klarnetei Lamažorā K.462, bija rakstīti Vīnes labākajam klarnetistam Antonam Štadleram. Abus saistīja arī cieša draudzība, sarakstē un ikdienā viņi viens otru uzrunāja par brāli, kā bija ierasts Brīvmūrnieku ložā, kurā abi atradās. Bet bija arī trešais. Viens no redzamākajiem Vīnes instrumentu meistariem – Teodors Locs. Visus trīs vienoja brīvmūrniecība, klarnete un mūzika. Šis ir viens no piemēriem mūzikas vēsturē, kā, sadarbojoties komponistam, izpildītājam un instrumentu meistaram, rodas uzlabojumi instrumenta uzbūvē, kurus komponists nekavējoties steidz atklāt mūzikā, jo augstākminētie skaņdarbi radušies tieši šajā sadarbībā. Jaunā basetklarnete, kuras apakšējais reģistrs salīdzinājumā ar tā saucamo A klarneti paplašināts par četriem pustoņiem, Antona Štadlera rokās Mocarta Klarnetes kvintetā un koncertā demonstrē savas labākās īpašības – maigu un samtainu skanējumu, kas Mocarta ieskatā lieliski imitē cilvēka balsi. Bet kā tad šī Mocarta klarnete saistīta ar Rīgu? Stāsts jāturpina ar to, ka Mocarta un Štadlera draudzība nebija tik viennozīmīgi saulaina. Daudzi Štadleru uzskatīja par krāpnieku, kurš regulāri iekuļas naudas grūtībās un izmanto Mocarta pieķeršanos un draudzību, aizņemoties no viņa naudu un tā arī nekad neatdodot… Turklāt pēc Mocarta pāragrās nāves 1791. gadā, kad daudzi Mocarta draugi visādi centās palīdzēt finansiālās grūtībās nonākušajai Mocarta atraitnei, Antons Štadlers necentās sniegt jelkādu atbalstu sava mirušā drauga sievai. Vēl vairāk – uz Mocarta atraitnes Konstances lūgumiem atdot viņai Antona Štadlera rīcībā esošos Klarnetes kvinteta un koncerta vērtīgos manuskriptus Štadlers atbildēja, ka koncertturnejas laikā viņam soma ar partitūrām un basetklarneti tikusi nozagta. Mocarta atraitne vēstulē izdevējam Johanam Andrē raksta, ka ir pilnīgi pārliecināta, ka Štadlers vērtīgās partitūras un instrumentu ir ieķīlājis vai pārdevis. 1794. gadā, kad Rīgā tiek izsludināts klarnetista Antona Štadlera koncerts, afišu rotā basetklarnetes attēls un koncerta pieteikumā īpaši atzīmēts, ka klausītājiem būs iespēja dzirdēt šo instrumentu. Todien rīdzinieki klausījās leģendāro klarnetistu un unikālo instrumentu, bet četrus gadus ilgušā koncertceļojuma laikā, kura maršruts vijās cauri Vācijas teritorijai un arī gar Baltijas jūras krastu, instruments bija neatgriezeniski pazaudēts. Kurš gan to būtu domājis, ka divus gadsimtus vēlāk tieši šī Rīgā drukātā afiša ar basetklarnetes attēlu kalpos par vērtīgu izziņas avotu pētniekiem un instrumentu meistariem mūsdienās, rekonstruējot pazaudēto instrumentu? Šāds ambiciozs projekts, kas ilga trīs gadus, ticis aizsākts jau mūsu gadsimtā, kad zviedru klarnetists Štefans Hargs un britu instrumentu meistars Gajs Kaulijs nolēma pēc basetklarnetes attēla uz Rīgā drukātās koncertafišas atkal likt ieskanēties šim instrumentam. Nu gluži tādā pašā tandēmā, kā reiz Vīnē Teodors Locs kopā ar Antonu Štadleru strādāja pie oriģinālā instrumenta! Un viņus visus pāri gadsimtiem vieno Mocarta pārpasaulīgā mūzika. Šajā video redzams rekonstruētais instruments un arī Štefans Hargs, atskaņojot Mocarta klarnetes kvintetu.  

Utilization isn't just a metric — it's the key to unlocking profitability, clarity and accountability across your entire team. In this episode, Michael Daoud, Founder and CEO of Visus LLC, sits down with us to share how transparency in utilization can transform operational efficiency in professional services firms. He highlights the value of role-based utilization targets and the importance of weekly over monthly KPI tracking for agility. Key Takeaways:(00:54) Making utilization transparent directly impacts revenue and profitability.(01:44) Custom data pipelines using PSA platforms offer richer insights than native reports.(03:27) Daily time entries are essential for real-time visibility.(05:44) Color-coded bar charts inspire self-correction without management pressure.(09:46) Transparency prevents idle bench time and promotes strategic internal initiatives.(12:17) Weekly tracking allows earlier course correction than monthly reviews.(14:24) Teams can start with spreadsheets before building advanced data warehouses.(16:09) Team members can access their utilization data anytime without waiting for reports.Resources Mentioned:Michael Daoudhttps://www.linkedin.com/in/michaeldaoud/Visus LLC | LinkedInhttps://www.linkedin.com/company/visus-llc./Visus LLC | Websitehttps://visusllc.com/This episode is brought to you by Content Allies.Content Allies helps B2B tech companies launch revenue-generating podcasts and build relationships that drive revenue through podcast networking. We schedule interviews with your ideal prospects and strategic partners so that you can build relationships and grow your business. You show up and have conversations, we handle everything else. Learn more at ContentAllies.com. #B2B #BusinessLeaders #Leadership

Aizvadītajā nedēļā VEF Kultūras pils kamerzālē jau septīto reizi tika pasniegtas folkloras gada balvas „Austras koks”. Tas ir viens no augstākajiem apbalvojumiem folkloras jomā Latvijā. Nominācijā „Aktivitātes folkloras jomā 2024. gadā” balvu saņēma Daugavpils Vienības nama Latviešu un latgaliešu kultūras centra „Tradīciju māja” un folkloras dziesmu un deju kopa „Svātra”. Balvu nominācijā „Mūža ieguldījums” saņēma Austris Grasis un Lidija Jansone, nominācijā „Latviskās dzīvesziņas kopšana un daudzināšana” balvu saņēma Aīda Rancāne un folkloras kopa „Grodi”, „Iedvesmas balva par gada publikāciju” tika pasniegta Latvijas Universitātes Literatūras, folkloras un mākslas institūta Latviešu Folkloras krātuvei. Folkloras dziesmu un deju kopa „Svātra” Daugavpilī darbojas jau trīs gadu desmitus, šobrīd savā kolektīvā pulcējot pāri par 30 dziedošus un dejojošus daugavpiliešus un apkaimes iedzīvotājus. Visus viņus vieno vēlme saglabāt, attīstīt un popularizēt latviskās tradīcijas, stāsta kopas vadītāja un idejas autore Sarmīte Teivāne. Saņemtā balva „Austras koks” ir veltījums visiem, kuri ar mīlestību un cieņu uztur dzīvu latviešu tautas kultūru. Tās saņemšana iedvesmo vēl dziļāk izprast mūsu saknes – senčus, novērtēt sevi šodien un apzināties atbildību par nākamajām paaudzēm, saka „Svātras” vadītāja Sarmīte Teivāne, un šī balva jau nav novērtējums tikai par pērn paveikto folkloras jomā, tas ir tiešām darbs un kopta dzīvesdziņa 30 gadu garumā. Daugavpils Vienības nama „Tradīciju mājai”, kas arī saņēma „Austras koka” balvu folkloras aktivitāšu rīkošanā pērnajā gadā, šogad aprit jau pieci gadi. Šī tradīciju māja kļuvusi par nozīmīgu kultūrtelpu Daugavpilī, kur tiek krātas un popularizētas tradicionālās kultūras vērtības. Par to, kas šeit notiek, stāsta „Tradīciju mājas” vadītāja Baiba Pankjāne. Šajā mājā ir arī viedais galds, kur notiek iepazīšanās ar senajām tradīcijām un amatiem. Taču lielākoties šī latviskā kultūrtelpa Daugavpilī ir pulcēšanās vieta, lai reāli iemēģinātu savu roku un iemācītos dažādās latvju senās amatu un tradīciju prasmes, bieži vien muzikantu pavadībā.

Stāsta flautiste Liene Denisjuka-Straupe Izsakoties Jura Ābola vārdiem, "intonēma ir runas zīme un katrai no tām piemīt noteikta emocionāla nokrāsa". No komponista Andreja Selicka esmu saņēmusi Jura Ābola traktātu par intonēmām. Darbs ir rakstīts ar rakstāmmašīnu, un nu jau apdzeltējušās lappuses nav iesietas. Materiāls ir ticis uzglabāts vien plāna kartona mapē un titullapa ir nozudusi. Ar darbu ir iespējams iepazīties, sākot no satura rādītāja, un, spriežot pēc 1. nodaļas nosaukuma "Valodas un mūzikas mijiedarbības estētiski filosofiskie aspekti", arī kopējais darba nosaukums varētu būt līdzīgs. Citām nodaļām nosaukumi nav piedēvēti. Darba rakstīšanas gads varētu būt 1977., vadoties pēc literatūras atsaucēm un 1977. gada avots ir darbā jaunākais. Traktātam ir piecas nodaļas un katrai no tām ir vairākas apakšnodaļas. Intonēmas ir aprakstītas 3. nodaļas 2. apakšnodaļā 53. lappusē. Lūk, kādu definīciju intonēmām piedēvē Juris Ābols: "Intonēma – ar šo jēdzienu mēs negribam uzstiept mūzikas zinātnei kādus lingvistiskus postulātus vai preambulas. […] Kamēr pirmatnējam cilvēkam vēl nebija attīstījusies skaņas augstuma sajūta, nevar būt runas par kādu muzikālu uztveri vai pat psihiskiem un emocionāliem muzikālo izjūtu veidojošiem spēkiem. Šie spēki sākumā darbojās valodas spēju attīstīšanas virzienā. Tad, kad šīs spējas bija nonākušas uz zināma attīstības līmeņa tālākas komunikatīvas pilnveidošanās nolūkos, valoda sāka muzikalizēties. Kā tas notika? Liekas, ka šeit vispirms darbojās p a t s k a ņ u  s i m b o l i k a, un viens no primitīvākajiem jēdzieniem, ko pauda vēl runāt neprotošais neandertālietis, bija "liels" – vai arī šī jēdziena pretstats – "mazs". Varam puslīdz droši apgalvot, ka šiem jēdzieniem sava pirmatnējā veidā atbilst attiecīgi patskaņi "i", "u" vai "o". Lai significētu mazu dzīvnieku, neandertālietis izrunāja vai intonēja attiecīgi augstākā un zemākā balsī. Šos jēdzienus padara skaidrākus attiecīgo patskaņu dubultošana vai akcentēšana. Piemēram, varēja teikt: "i-i-i-i" augstāk intonēts, quasi staccato un "o-o-o" zemāk intonēts, pie kam šī intonācija varēja būt arī krītoša, stiepta, izdziestoša. Loģiski, ka mazs priekšmets vai dzīvnieks varēja izraisīt prieku, bet liels dzīvnieks varēja iedvest bailes un šeit ir visu signifikantu saskares punkts. Bailes savienotas ar kustību, savu izpausmi varēja rast augstu intonētā un stieptā "o" vai "a" utt." Ņemot vērā to, ka Juris Ābols nesniedz priekšvārdus saviem skaņdarbiem, tad intonēmas tulkojums ir atstāts gan katra izpildītājmākslinieka interpretācijas, gan arī klausītāja individuālās uztveres ziņā. Interesanti, ka muzikoloģe Inese Lūsiņa atceras: "Viņā eksperimentētāja, meklētāja gars vienmēr gāja kopā ar humoru. Piemēram, viņš ļoti daudz strādā ar fonēmām, ar tādām pirms valodas esošām formām, kur dažādas intonācijas, tas, kā tu pasaki dažādas zilbes, izsaka to, ko mēs šodien mēģinām izteikt ar valodu, ar gatavu noformulētu valodas formu un it kā nepārprotamiem vārdiem un teikumiem, kas ir ielikti kontekstā. Un viņa konteksts bija fonēmas pašas. Juris Ābols līdz šim pirmais un vienīgais mūsu dadaists mūzikā." Nedaudz atskatoties vēsturē, ir zināms, ka dadaistu mūzikas žanru klāstā bija arī viņu iedomāta "Negro" mūzika. Tās izcelsme bija rodama Tristana Carā vaļaspriekā – afrikāņu masku kolekcionēšanā un arī darināšanā, bez tam nereti dzejas priekšlasījumos tika lietotas maskas. 1916. gadā Carā un Balss aizrāvās arī ar mūzikas (skaņas) un dzejas apvienojumu. "Negro" mākslas eksperimentu pamatā bija idejas par to, kā mūzika vai runa varētu izklausīties pirmatnējo cilvēku izpildījumā, piemēram, aizvēsturiskai mūzikai nav nosakāma tonalitāte un tajā nav nekādu likumu, ir tikai noskaņa vai transa stāvoklis. Tā pati ideja attiecās arī uz dzeju un fonētiku – pateiktais vārds vai nevārds zaudēja savu jēgu, tāpat kā mūzika zaudēja savus izteiksmes līdzekļus. Brīdī, kad pazuda vārda un mūzikas jēga, tad pāri palika ritma funkcija, kas savā veidā padarīja dzeju par "mūziku" un mūziku par "dzeju". Kopumā par vārda būtību dadaistiem bija arī savi īpaši uzskati, kas tika pausti jau sākot kopš "Voltēra kabarē" atklāšanas vakara. Jau toreiz Balls savā manifestā deklarēja: "Man negribas vārdus, ko izgudrojuši citi. Visus vārdus ir izgudrojuši citi. Es gribu pats savu bezjēgu (…) Katrai lietai ir savs vārds; vārds pats tur ir kļuvis par lietu. Kāpēc koks nevarētu saukties "pupluš" vai "pluplubaš", ja ir lijis? Un kāpēc vispār ir kaut kā jānosauc? Vai tiešām visam jāatskan no mūsu mutēm? Vārds – vietai šai tagad ir dzemdību sāpju smārds, vārds, mani kungi, ir kļuvis par visaugstākā ranga publisku nodarbošanos."  

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo are live from the Hawaiian Eye meeting with guests Paul Singh, MD, Candy Simerson, Jeffrey Goldberg, MD, PhD, and Roger Goldberg, MD, MBA. Welcome to the Eyeluminaries podcast :02 Review of episode 30 3:23 Intro of Paul Singh, MD 3:40 What are the future trends in glaucoma you're most excited about? 5:10  What challenges do you see in running your practice that didn't exist in your dad's day? 8:36 You've got a great medical office, a very busy consulting and research practice, you play in a band and you have a young family. What advice would you give others in keeping it all in balance? 12:09 Besides your dad and the two of us, who do you look up to in eye care? 14:45 Singh sings a Funkadesi song 18:16 Intro of Candy Simerson 20:36 When you come into a new practice to consult, what are the most common areas you see where improvement can be made? 21:41 What about the finances? What areas in finances do you see where improvement can be made? 24:27 In your many years in ophthalmology, what are the biggest challenges you've experienced? 26:10 What type of practice should consider a sale to private equity? What type of practice should not? 29:34 What advice would you give a company representative who wants to win business from a big ophthalmology practice? 32:29 Intro of the Goldbergs 36:25 Jeff Goldberg, MD, PhD 36:50 Roger Goldberg, MD, MBA 37:21 Jeff, why glaucoma instead of retina? 38:43 Roger, why retina instead of glaucoma? 39:37 Mazzo discusses neuroprotection in retina and glaucoma. 41:14 What is entrepreneurship like today? What's your advice? What is challenging and what is positive? 43:10 Mazzo discusses being realistic about innovations. 48:30 What is private practice like today? 49:31 How do cornea specialists better understand glaucoma specialists? 53:05 How do cornea specialists better understand retina specialists? 54:13 Tell us about emmecell. 55:50 Preview of episode 32 59:19 Give us your feedback 1:00:18 Thanks 1:00:30 Jeffrey Goldberg, MD, PhD, is professor and chair of ophthalmology at the Byers Eye Institute at Stanford University and a member of the National Academy of Medicine. Roger Goldberg, MD, MBA, board certified by the American Board of Ophthalmology and is an active member of the American Society of Retinal Specialists, the Retina Society and the American Academy of Ophthalmology. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Candy Simerson is the senior vice president of practice operations at Vision Integrated Partners. I. Paul Singh, MD, is the president of The Eye Centers of Racine & Kenosha, Ltd., founded in 1981 by his father, Dr. Kanwar A. Singh. He is a founding member of the band, Funkadesi, a mix of Indo-Afro-Caribbean style music. The band tours the world spreading the message “one family, many children.” We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for the Goldbergs, Simerson and Singh at the time of publication.

Nacionalinė mokėjimo agentūra skelbia, kad mažinant biurokratinę naštą, nerizikingiems projektams trumpinamas kontrolės laikotarpis. Tai priklausys ir nuo patikrų, ar jos bus pozityvios. Kaip tikina Lietuvos jaunųjų ūkininkų ir jaunimo sąjungos pirmininkė Rūta Jurgaitė, nepada-ryti klaidų ūkininkams sunku. Antrus metus ūkininkaujantis Plungės r. ūkininkas Simas Jonu-šauskas sako, kad patikrų laukia su nerimu, nors projekto metu teko samdytis ir konsultantą. Plačiau naują tvarką pakomentuos NMA departamento direktorė Genovaitė Beniulienė.Daržininkystės ūkį su šeima Vilniaus rajone puoselėjusi Božena Lazovska Kuzborska nebūtų patikėjusi, kad kada nors augins ožkas, o štai dabar ji didelio ožkų ūkio šeimininkė. Iš ožkų pieno gaminami desertai, brandinti sūriai. Moteris džiaugiasi, kad jos sūrių paklausa didelė ir planuoja plėtrą.Rubrikoje ,,Gamtininko komentaras“ Gamtos tyrimų centro Augalų patologijos laboratorijos doktorantas Martynas Dėlkus papasakos, kuo augalams grėsmingos yra fitoplazmos.Ved. Rūta Simanavičienė

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news and trends and chat with Steven Dell, MD, about his career and the creation of markets in the field of ophthalmology. Welcome to the Eyeluminaries podcast :02 Review of episode 29 1:28  Bausch + Lomb acquires Elios Vision 2:07  ImprimisRx awarded $34.9 million in trademark infringement suit against OSRX 5:00  Study of atropine-based myopia treatment fails to meet primary efficacy endpoint 7:31  Intro of Steven Dell, MD 11:20 You have created markets with new technologies and companies. Can that continue in today's market? 13:28 Dell discusses presbyopia market development. 14:11 You created a questionnaire that you used in your practice, which has become known as the Dell Questionnaire. What do we need to do better in treating our cataract patients? 16:20 What technologies are going to be the most important in the future? 20:24 What has changed in your office environment, i.e., the role of ODs, admin, staff? 22:00 Dell discusses Lindstrom's Integrated Eye Care Delivery Model. 23:08 What advice would you give a younger Steven Dell? 27:16 Neurotech Pharmaceuticals announced that chief commercial officer Scott Hunter died on Dec. 3. 33:06 Give us your feedback 34:43 Thanks 34:51 Steven J. Dell, MD, is a board-certified ophthalmologist in Austin and the Medical Director of Dell Laser Consultants. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Dell at the time of publication.

In this special crossover episode, Eyeluminaries hosts Jim Mazzo and John A. Hovanesian, MD, FACS, are joined live by Susan MacDonald, MD, and Cathleen McCabe, MD, at Eyecelerator 2024 in Chicago, IL. Intro :07 Welcome to the Eyeluminaries podcast 3:14 In this episode 5:02 Intro of Susan MacDonald, MD, and Cathleen McCabe, MD 5:11 What started you on this journey to do humanitarian work? 5:30 MacDonald discusses the role of parents in defining of happiness. 10:56 Hovanesian discusses the background of his humanitarian work in Armenia. 11:36 What about the funding of these humanitarian projects? 12:50 What are your stories from doing humanitarian work? 14:11 What advice to do you have for physicians who want to get involved in humanitarian work? 18:55 Hovanesian discusses the commonalities in MacDonald and McCabe's humanitarian missions. 22:23 McCabe discusses the commonalities in Hovanesian and MacDonald's humanitarian missions. 22:50 MacDonald discusses how her humanitarian work began. 23:28 Thank you. 27:05 MacDonald talks about the ophthalmic industry and their contribution to humanitarian work. 27:51 McCabe discusses ways physicians can get involved in humanitarian work without having to travel overseas. 28:42 Visit ACE Global, Cybersight or Operation Sight to get involved. 28:54 Mend the Gap podcast 30:49 Preview of episode 30 32:17 Give us your feedback 32:44 Thanks 33:17 Thoughts 33:27 Visit the ASCRS Foundation to get involved in Operation Sight. 34:20 Thank you for listening! 35:17 Don't forget to like and subscribe to Mend the Gap and Eyeluminaries! 35:39 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Susan MacDonald, MD, is president of Eye Corps and associate clinical professor at Tufts School of Medicine. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Cathleen McCabe, MD, is chief medical officer of Eye Health America and medical director of The Eye Associates in Sarasota, FL. We'd love to hear from you! Send your comments/questions to podcast@healio.com. Follow us on X (formerly Twitter) @Healio_OSN. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. MacDonald and McCabe report no relevant financial disclosures.

Įsivaizduokite šiuolaikinį pasaulį, kuriame vaikšto mamutai, o žmonėms sulaukti savo šimtojo gimtadienio taip įprasta, kaip šiandien pilnametystės. Su mokslininkų komanda Miglė Tomkuvienė leidosi į tobulėjantį gyvybės mokslų pasaulį, rašydami mokslo populiarinimo knygą apie tai, kokį vaidmenį atlieka informaciją koduojanti molekulė – RNR. Nuo jos priklauso ne tik tai, kaip augame ir gyvuojame, bet ir kokiomis ligomis sergame ir kaip senstame, o pritaikymas kasdienybėje ateityje gali pakeisti mūsų pasaulį.Kaip ši molekulė gali padėti prikelti seniai išnykusias gyvūnų rūšis? Kaip ji susijusi su mūsų senėjimu ir jaunystės paslapčių paieškomis?Pokalbis su Vilniaus universiteto Gyvybės mokslų centro mokslininke, rašytoja dr. Migle Tomkuviene.Ved. Ignas Klėjus

Prisiminsime vokiečių supergrupę, kokios iš tiesų ir nebuvo: studijos kvietimu keletas krautroko talentų susibūrė muzikuoti, o vardu „Cosmic Jokers“ 1974 metais buvo išleistas plokštelių ciklas ir sudarytas iš įrašų, nenumatytų publikacijai. Visus tolesnius nesutarimus pranoko tai, kaip klausytojų pamėgtos tapo šios plokštelės.Tuo tarpu Rytų Vokietijoje kompozitorius pseudonimu „Kosmischer Läufer“ kūrė muziką sportinėms treniruotėms ir iš archyvų garso įrašai buvo iškelti tik dabar, sulaukė didelio dėmesio... tačiau šis „kosminis bėgikas“ gal iš tiesų yra jau naujo tūkstantmečio slaptasis muzikantas?Ved. Lukas Devita.

Šajās dienās risinājušies vairāki analīzes vērti notikumi, tāpēc mums bija jāizdara izvēle. Pamatā šoreiz uzmanību fokusēsim austrumu virzienā. Jaunievēlētais Savienoto Valstu prezidents Donalds Tramps ir licis saprast, ka viņa ārpolitikas centrā būs Amerikas attiecības ar Ķīnu. Abu lielvalstu attiecības ir saspringtas jau šobrīd, tomēr līdz ar prezidenta maiņu situācija varētu kļūt vēl sarežģītāka.Tas, kāda būs ASV politika attiecībā pret Ķīnu, var ietekmēt gan karu Ukrainā, gan Krieviju, protams, visu Āzijas reģionu. Interesants ir jautājums arī par Ziemeļkoreju, jo šīs valsts ļoti ciešā draudzība, kas tai tagad ir izveidojusies ar Krieviju, rada gan jaunus jautājumus, gan savus izaicinājumus, ko tas nozīmēs arī pašai Ziemeļkorejai, šai pasaules noslēgtākajai valstij? Bet nevar nepieminēt arī Tuvos Austrumus, kur no 27. novembra rīta spēkā ir stājies pamiers starp Izraēlu un grupējumu "Hezbollah". Aktualitātes analizē Austrumeiropas politikas pētījuma centra pētnieks Armands Astukevičs un Rīgas Stradiņa universitātes Politikas zinātnes doktorantūras vadītāja, Ķīnas studiju centra direktore, Latvijas ārpolitikas institūta Āzijas programmas direktore Una Aleksandra Bērziņa-Čerenkova. Milžu danči – Ķīnas un Rietumu attiecību visjaunākā vēsture 2020. gada 23. jūlijā, uzstājoties ar priekšlasījumu Ričarda Niksona Bibliotēkā Kalifornijā, toreizējais Savienoto Valstu valsts sekretārs Maiks Pompeo nāca klajā ar tēzi, ka tuvināšanās ēra starp Brīvo pasauli un komunistisko Ķīnu, kas iestājās pagājušā gadsimta septiņdesmitajos gados, ir galā. Ķīnas komunistiskais režīms īsteno negodīgu tirdzniecības politiku, zog intelektuālo īpašumu, pārkāpj cilvēktiesības Honkongā un Siņdzjanā un agresīvi uzvedas Dienvidķīnas un Austrumķīnas jūrās. Šī uzstāšanās zināmā mērā vainagoja attiecību pasliktināšanos starp Pekinu un Vašingtonu, kas iezīmējās Donalda Trampa pirmās prezidentūras četrgadē. Amerikāņu puses iniciēts, starp abām superlielvarām uzliesmoja tirdzniecības karš, apmainoties desmitiem miljardu vērtām ievedmuitas tarifu paaugstināšanas paketēm. Savienotās Valstis noteica arī ierobežojumus investīcijām un potenciāli militāriem mērķiem lietojamu tehnoloģiju eksportam uz Ķīnu, kā arī ķīniešu sakaru tehnikas importam, balstoties aizdomās, ka šī tehnika var tikt izmantota spiegošanai. Neiztika bez politiski motivētām sankcijām, visvairāk pret tām ķīniešu amatpersonām un organizācijām, kuras bija vainojamas brīvību žņaugšanā Honkongas autonomijā. Par vēl vienu sāpīgu momentu kļuva Pekinas režīma loma Covid-19 pandēmijas uzliesmošanā, noklusējot informāciju par infekcijas izcelšanos savā teritorijā un mēģinot slēpt pēdas. Nepiepildījās arī Pekinas cerības, ka būtiskas izmaiņas šai ziņā nesīs Trampa nomaiņa ar Baidenu Baltajā namā. Arī pie demokrātu administrācijas tarifi, sankcijas un kritiska retorika pret Ķīnas politiku palika nemainīga. Ķīnas kā drošības izaicinājuma piesaukšana parādījās NATO konceptuālajos dokumentos. Domājams, zemāko punktu Vašingtonas un Pekinas attiecības piedzīvoja 2022. gada augustā pēc Kongresa Pārstāvju palātas spīkeres Nensijas Pelosi vizītes Taivānā. Salīdzinoši daudz mierīgākas šai periodā bijušas Ķīnas attiecības ar Eiropas Savienību, kas gan, jāpiebilst, no Pekinas puses pamatā tiek realizētas kā attiecības ar atsevišķām dalībvalstīm. Spilgts piemērs bija Francijas prezidenta Emanuela Makrona un Eiropas Komisijas prezidentes Urzulas fon der Leienas pagājušā gada aprīļa kopīgā vizīte Ķīnā, kuras laikā Eiropas Savienības galvenās izpildinstitūcijas galva tika tur uzņemta teju kā Francijas prezidenta pavadošā persona. Tieši šī samita laikā Makrons izteicās, ka Eiropai vajadzētu mazināt savu stratēģisko atkarību no Savienotajām Valstīm un distancēties no iespējamās ASV un Ķīnas pretstāves Taivānas jautājumā. Kvalitatīvi gluži jauna situācija iestājās pēc Krievijas plaša mēroga iebrukuma Ukrainā. No vienas puses, Pekina ietur formāli neitrālu pozīciju, lielākoties atturoties ANO balsojumos par Krievijas agresijas nosodīšanu. Tomēr ir diezgan skaidrs, ka tieši Pekinas tehnoloģiskais atbalsts ražošanas iekārtu, dzinēju, mikroprocesoru, dažu specifisku ķimikāliju un citu militārajai ražošanai izmantojamu materiālu veidā ļāvis agresorvalstij līdz šim vest šo karu sev salīdzinoši labvēlīgā veidā. Kima zvaigžņu stunda Formālais iemesls, kāpēc Savienotās Valstis un to partneri deva Ukrainai atļauju apšaudīt Krievijas pamatteritoriju ar Rietumu piegādātajām raķetēm, ir Korejas Tautas Demokrātiskās republikas karavīru parādīšanās Ukrainas frontē. Kā ziņojuši Ukrainas mediji, raķešu triecienos esot nogalināti apmēram piecsimt ziemeļkorejieši un ievainots prominents Phenjanas režīma ģenerālis, kurš, acīmredzot, ieradies koordinēt savu tautiešu kaujas darbību Krievijas Kurskas apgabalā. Krievijas atbilde bijusi uz rūpnīcas „Južmaš” teritoriju Ukrainas Dņipro pilsētā tēmētā ballistiskā raķete „Orešņik”, kas gan neradīja nopietnus postījumus, taču daudzviet lika nervozi sarosīties tiem, kuri baidās no kodolkara draudiem. Galu galā minētais „Orešņik”, pagaidām vēl, kā tiek pausts, izmēģinājumu stadijā esošs izstrādājums, esot paredzēts aprīkošanai ar kodollādiņu. Totalitārās Ziemeļkorejas vadonis Kims Čenuns, domājams, jūt savu zvaigžņu stundu situšu. Viņš, kurš gadiem mēģinājis kutināt savam reģionam nervus ar kodolbruņošanās programmu, beidzot ticis pie reālas lomas globāla mēroga kodoldraudu „šovā”. Pēc Dienvidkorejas izlūkdienesta ziņām par lielgabalu gaļas piegādi no Kremļa saimnieka Kims pretim saņēmis pretgaisa aizsardzības iekārtas, taču netiek izslēgta iespēja, ka varētu tikt piegādāts arī kas tāds, kas noderētu nesējraķešu vai pat kodollādiņu ražošanā. Par Kima starptautiskā svara pieaugumu liek domāt arī 26. novembrī mediju izplatītā ziņa, ka jaunievēlētais prezidents Tramps apsverot iespēju aktivizēt abu dialogu. Vairākas tikšanās ar Kimu bija viens no ekstravagantākajiem Trampa pirmās prezidentūras starptautiskās politikas gājieniem, kaut beidzās bez nozīmīgiem rezultātiem. Visus prezidenta Baidena mēģinājumus uzsākt sarunas bez priekšnoteikumiem Ziemeļkorejas diktators ignorēja un vēl pagājušajā nedēļā, runājot militārās tehnikas sasniegumu izstādē Phenjanā, paziņoja, ka Ziemeļkoreja jau esot nesekmīgi izmēģinājusi visus iespējamos ceļus sarunām ar Savienotajām Valstīm, bet tās, kā bijušas, tā palikušas agresīvas un naidīgas. Sagatavoja Eduards Liniņš.

In this episode, Jim Mazzo and John A. Hovanesian, MD, FACS, are live from Eyecelerator with Mend the Gap hosts Susan MacDonald, MD, and Cathleen McCabe, MD, discussing their humanitarian work. Welcome to the Eyeluminaries podcast :02 In this episode :31 Intro of Susan MacDonald, MD, and Cathleen McCabe, MD 1:00 What started you on this journey to do humanitarian work? 2:18 MacDonald discusses the role of parents in defining of happiness. 7:47 Hovanesian discusses the background of his humanitarian work in Armenia. 8:24 What about the funding of these humanitarian projects? 9:38 What are your stories from doing humanitarian work? 10:59 What advice to do you have for physicians who want to get involved in humanitarian work? 15:43 Hovanesian discusses the commonalities in MacDonald and McCabe's humanitarian missions. 19:11 McCabe discusses the commonalities in Hovanesian and MacDonald's humanitarian missions. 19:38 MacDonald discusses how her humanitarian work began. 20:16 Thank you. 23:49 MacDonald talks about the ophthalmic industry and their contribution to humanitarian work. 24:39 McCabe discusses ways physicians can get involved in humanitarian work without having to travel overseas. 25:30 Visit ACE Global, Cybersight or Operation Sight to get involved. 25:38 Mend the Gap podcast 27:37 Preview of episode 30 29:05 Give us your feedback 29:25 Thanks 30:05 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Susan MacDonald, MD, is president of Eye Corps and associate clinical professor at Tufts School of Medicine. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Cathleen McCabe, MD, is chief medical officer of Eye Health America and medical director of The Eye Associates in Sarasota, FL. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. MacDonald and McCabe report no relevant financial disclosures.

Dukart žurnalistų turnyro čempionas ir MVP Augustas Šuliauskas, taip pat dukart čempionas Karolis Tiškevičius ir visai ne čempionas Jonas Miklovas aptaria krepšinio įvykių kupiną savaitgalį – nuo pasaulį apskriejusio Lonnie Walkerio dėjimo iki sąlygų Russellui gauti Lietuvos pilietybę. Tinklalaidės partneriai: – Novastar.lt – geriausiai vertinama internetinė elektronikos prekių parduotuvė pagal evertink.lt (2024-11-25) skelbia BLACK FRIDAY savaitės pradžią. Paskubėk įsigyti elektronikos prekes su nuolaida. Užsuk į www.novastar.lt  – Užsisakyk „Telia Play” ir mėgaukis mėgstamomis krepšinio rungtynėmis, kad ir kur bebūtum! Plačiau: https://www.telia.lt/privatiems/televizija?be-isipareigojimu  – Nealkoholinis alus „Gubernija”, daugiau informacijos – https://gubernija.lt/  – NAUJIENA - Shop.BasketNews.lt personalizuoti kalėdiniai rinkiniai! Rinkis iš keturių skirtingų dydžių ir nustebink savo artimąjį! Apsilankykite https://shop.basketnews.lt/pages/kalediniai-rinkiniai ir pasinaudokite geriausiais kalėdiniais pasiūlymais jau šiandien. Temos: Įvykių kupinas savaitgalis (0:00); Visus šokiravęs dėjimas (1:15); Ar Walkeris – šiuo metu geriausias gynėjas Eurolygoje? (4:55); Geriausia sezono atmosfera Kaune (10:11); Merui vietą parodę fanai (12:04); Daug komandai reiškiantis Smailagičius (24:27); Apie save vėl priminęs Sirvydis (26:18); Skambi frazė apie Dimitrijevičiaus pasirodymą (28:33); Rekordai – prieš Kurtinaitį (29:37); Ar makedonų treneris domisi krepšiniu? (37:50); Kas kovos dėl pagrindinio dvyliktuko? (45:47); Finalas prieš Lekšą ir nemaloni situacija (47:51); Žurnalistų čempionų titulas lieka ten pat (48:49); Aikštėje vis dar (per) karštas Skaisgirys (52:59); Metų apiplėšimas Slovakijoje (59:24); Paminklo vertas Šengelija ir kitos atrankos intrigos (1:06:27); Už ar prieš Russellą rinktinėje? (1:15:52); Ką turi padaryti, kad vadintumeisi lietuviu? (1:23:11).

Riccardo Falcinelli"Visus"Storie del volto dall'antichità al selfieEinaudi Editorewww.einaudi.itScrittori in Città, CuneoSabato 16 novembre 2024, ore 14:30Centro Incontri della Provincia, Sala Bluwww.scrittorincitta.itBookCity, MilanoDomenica 17 novembre 2024, ore 18:00Triennale, Salone d'onorewww.bookcity.it«Cosa c'è di piú facile del volto? Tutti ne abbiamo uno, e abbiamo a che fare con quello degli altri. Eppure, di tutte le cose che ci capita di guardare, il volto rimane la piú enigmatica».Pubblicando i selfie su Instagram ci poniamo gli stessi problemi che si è posto ogni artista e comunicatore nella Storia: cercare di rendere una faccia piú eroica, autorevole, addirittura divina. O magari conferirle valori morali, come i pittori del Rinascimento, che ritraevano i sovrani accanto a una colonna o una tenda per esprimere maestà e prestigio. La faccia è la parte del corpo piú soggetta ad attribuzioni di senso: anche se tendiamo a considerarli qualcosa di «naturale», i volti sono sempre una costruzione culturale. Da Alessandro Magno a Rita Hayworth, da Elsa di Frozen al bambino della Kinder, dall'icona di Cristo fino alle foto sulle lapidi dei nostri nonni, con immensa profondità di analisi e verve narrativa, Falcinelli inventa una «facciologia», chiamando in causa l'arte, la semiotica, le neuroscienze, la storia politica, la moda e i cosmetici. Perché il volto che ci costruiamo può determinare la vita che faremo.Riccardo Falcinelli (1973) è uno dei piú apprezzati graphic designer italiani. Per Einaudi ha pubblicato Critica portatile al visual design (2014), Cromorama (2017), Figure (2020), Visus. Storie del volto dall'antichità al selfie (2024) e ha curato Filosofia del graphic design (2022). I suoi libri sono tradotti in inglese, spagnolo, russo, cinese, coreano e giapponese.www.falcinelliand.coIL POSTO DELLE PAROLEascoltare fa pensarewww.ilpostodelleparole.itDiventa un supporter di questo podcast: https://www.spreaker.com/podcast/il-posto-delle-parole--1487855/support.

Vēsturiska spēlfilma par Pirmajiem Vispārīgajiem latviešu dziedāšanas svētkiem, cilvēkiem, kuru idejas un darbi ierakstīti Latvijas kultūras vēsturē, un nozīmīgām vietām vēsturisko notikumu dzimšanā. Kultūras rondo saruna ar filmas „Zeme, kas dzied” režisoru Māri Martinsonu, scenārija līdzautoru Daini Īvānu, aktieri Vili Daudziņu, kurš atveido Bernhardu Dīriķi, un komponistu Jēkabu Jančevski.   Filma, kas skar mūs visus. Visus latviešus un Latvijas valsti, jo toreiz – 1873.gadā – mēs kā nācija pirmoreiz satecējām kopā vienā dziesmā. "Zeme, kas dzied". Cik svarīga ir vēsturiskā precizitāte iepretim tai drāmai un konfliktam, kas patiesībā norisinājās dziedāšanas svētku organizatoru starpā? Kā sieviešu balsis parādījās līdz tam ierastajā tikai vīru balsu kopā? Režisora Māra Martinsona un scenārija līdzautora Daiņa Īvāna vēsturiskā spēlfilma "Zeme, kas dzied" – stāsts par latviešu nācijas dzimšanu Pirmo latviešu dziedāšanas svētku laikā 1873. gadā – uz kinoekrāniem nonāks 8. novembrī, ieskandinot Latvijas valsts svētkus. Savukārt 15. novembrī iznāks Daiņa Īvāna grāmata "Zeme, kas dzied. 1873" Starp filmas vēsturisko personāžu atveidotājiem ir Andris Bulis (Rihards Tomsons), Ainārs Ančevskis (Jānis Frīdrihs Baumanis), Vilis Daudziņš (Bernhards Dīriķis), Nauris Brikmanis (Krišjānis Kalniņš), Andris Keišs (Atis Kronvalds), Ģirts Ķesteris (Jānis Cimze). Savukārt Marta Lovisa Jančevska (Anna Līdumnieks), operdziedātāja Marina Rebeka (Zelma Līdumnieks), igauņu aktieris Priit Pius (Jurģis Grietēns) un citi atklāj stāstu par latviešiem ceļā uz pirmajiem svētkiem. Filmas režisors ir Māris Martinsons, operators Jānis Jurkovskis, scenāriju veidojuši režisors kopā ar Atmodas laika aktīvistu un žurnālistu Daini Īvānu. "Zeme, kas dzied" komponists – Jēkabs Jančevskis, mākslinieks Mārtiņš Kalseris, kostīmu māksliniece Katrīna Liepa, grima māksliniece Aija Beata Rjabovska, gaismu mākslinieks Juris Zemītis, skaņu režisors Jānis Eglītis, aktieru atlases režisore Gunita Groša, izpildproducentes Inga Zeile, Madara Kalniņa, līdzproducente Anneli Ahven (Igaunija), producente Linda Krūkle.

Gamtininkas Selemonas Paltanavičius pristato savo 100-ąją knygą – šįkart knygą visiems „Su gamta kišenėje. Vaikystės nutikimai“, kurioje aprašo savo, kai buvo vaikas, pirmuosius susidūrimus su gamta. Kaip įmanoma per gyvenimą parašyti 100 knygų?Policija ragina šiomis dienomis – per Visus šventuosius ir Vėlines – vairuoti atidžiau, elgtis mandagiai prie kapinių ir įspėja apie planuojamus reidus blaivumui tikrinti. Kaskart per tokius reidus policija nustato daug išgėrusių vairuotojų. Kiek jūs atsižvelgiate į pareigūnų prašymus?Veikti pradėjo mirusiųjų „Facebook“ – platforma „Neverlost.lt“, kurioje galima kaupti prisiminus apie mirusiuosius. Šią platformą sukūrė verslininkas Ričardas Čepas, kurį tai padaryti paskatino jo paties brolio netektis.Skuodo rajone Visgaudžių kaime savo prosenelių sodyboje, mamos gimtinėje, gyvenantis 70-metis ūkininkas Algerdas Rozga – išskirtinės giminės atstovas, vertinantis ir dirbamos žemės kvapą.Ved. Edvardas Kubilius

„Europos ūkininkų kongresas 2024“ buvo 11-ą kartą „Copa–Cogeka“ sukviestas Europos ūkininkų forumas. Rumunijos sostinėje Bukarešte į jį susirinko per 400 žemdirbių atstovų, pranešėjų ir svečių. Pagrindinė tema, į kurią atsakymo ieškota kongreso metu – žemės ūkio šakos konkurencingumo, produktyvumo stiprinimas naujojo politinio ciklo laikotarpiu. Ar rastas atsakymas į šį ir kitus žemdirbiams opius klausimus? Išsamiau – Žemės ūkio bendrovių asociacijos prezidentas Eimantas Pranauskas.Anksčiau gyvenę Kretingoje ir vertęsi augalininkyste, Monika ir Raimondas Pareigiai prieš 8 metus kėlėsi į Genčų Medsėdžių kaimą. Jie pasirinko auginti mėsinius limuzinų veislės galvijus. Tad dabar ūkyje 120 grynaveislių ir mišrūnų galvijų. Dalį jų nuolat skersdami, kokybišką mėsą sugeba greitai parduoti, kartais susidaro kelių mėnesių pirkėjų eilė. Gyvulių šeima laiko tiek, kiek pati sugeba užauginti ir tinkamai prižiūrėti.Didelėje mišrų ūkį turinčioje Šakių rajono Griškabūdžio žemės ūkio bendrovėje darbų ratas nesustoja visus metus. Pasibaigus didiesiems laukų darbams, dar ne visa technika po stogu. Visus metus juda galvijų fermas aptarnaujanti technika. Pasak bendrovės technikos inžinieriaus Tomo Puskunigio, laisvesnis metas dabar išnaudojamas remonto dirbtuvėms pertvarkyti, darbo ir poilsio sąlygoms mechanizatoriams gerinti.Vokietijoje plintant mėlynojo liežuvio ligai, avių augintojai jaučiasi apleisti valdžios.Ved. Regina Montvilienė

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news and trends and chat with Tom Mitro about his career and impact in ophthalmology. Welcome to the Eyeluminaries podcast :02 Review of episode 26 :58 FDA grants fast track designation to brepocitinib for noninfectious uveitis 1:42  I. Howard Fine, MD, esteemed ophthalmologist, dies 3:54 First subjects dosed in phase 3 trial of phentolamine ophthalmic solution for presbyopia 5:48 LENZ Therapeutics submits NDA for drops to treat presbyopia 7:57 Intro of Tom Mitro 10:40 Tell us about your journey in ophthalmology 12:38 Tell us about the new dry eye drug from Signal 12. 15:53 How much sensation is on the forehead if the drug is well tolerated? 24:13 What are your thoughts on the current ophthalmology market? 26:01 Tell us a funny story about Jim Mazzo and about John Hovanesian. 28:51 Preview of episode 29 33:25 Give us your feedback 34:34 Thanks 34:50 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Tom Mitro is the president and chief operating officer for Aerie Pharmaceuticals. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Mitro at the time of publication.

Gamtos tyrimų centro mokslininkas Gintautas Vaitonis aiškina, kodėl plačiažnyplius vėžius sunku veisti, kokiu būdu į Lietuvą atkeliavo invaziniai vėžiai ir primena, kad nuo spalio 16 d. visose upėse yra draužiamas vėžių rūšių gaudymas, išskyrus invazines rūšis – žymėtuosius ir rainuotuosius vėžius galima visus metus.Aplinkosaugininkė Akvilė Jagučinskytė, kalbėdama apie antrinį vandens panaudojimą, sako, kad nors Lietuvoje pakankamai geros kokybės požeminio vandens, svarbu atkreipti dėmesį į vandenį, kuris jau buvo panaudotas. Ji akcentavo, kad išvalytas vanduo gali būti naudojamas gatvių plovimui, gėlių laistymui ir net žemės ūkyje, kur klimato sąlygos tampa vis sudėtingesnės.Ved. Selemonas Paltanavičius ir Alvyda Bajarūnaitė

Jūsų saugumas yra mūsų saugumas, - sako Lietuvoje viešintis Vokietijos gynybos ministras Borisas Pistorijus.Vakar Vilniaus „Akropolyje“ vyresnio amžiaus moteris pagrobtas 6,5 m. vaikas buvo surastas ir namo grįžo gyvas ir sveikas. Ką reikia žinoti tėvams, norintiems apsaugoti savo vaikus?Ukrainos prezidentui Volodymyrui Zelenskiui viešint Jungtinėse Valstijose, gilėja konfliktas tarp jo ir kandidato į prezidentus Donaldo Trumpo, o Respublikonų partijos vadovybė imasi veiksmų diskredituoti jo vizitą. Pradėtas parlamentinis tyrimas dėl Zelenskio vizito Pensilvanijos amunicijos gamykloje, kaltinant jį dalyvavus Demokratų partijos rinkiminėje kampanijoje, tuo metu Atstovų Rūmų pirmininkas Maikas Džonsonas paskelbė raginimą atleisti Ukrainos ambasadorę Vašingtone.Tęsiantis susišaudymams tarp Izraelio ir grupuotės „Hezbola“ Libane, Amerikos ir Prancūzijos lyderiai kartu reikalauja nedelsiant skelbti paliaubas. Izraelis paliaubų gaimybę atmeta.Vilniaus rajone atidarytas pirmasis Baltijos šalyse genų terapijos centras. Jis teiks pažangias genų terapijos vaistų vystymo ir gamybos paslaugas farmacijos įmonėms Europoje ir JAV. Centre bus atliekami inovatyvūs genų terapijos moksliniai tyrimai ir komponentų gamyba.Nuo šiandien vairuotojai, važiuojantys greitkeliu iš Klaipėdos Vilniaus link galės važiuoti Kleboniškio arba Alfonso Meškinio tiltu per Nerį. Eismo organizavimas važiuojantiems Klaipėdos kryptimi nesikeičia. Visus tilto rekonstravimo darbus planuojama baigti šių metų pabaigoje.Ved. Agnė Skamarakaitė

Par Baltvilka poti bērnu literatūras pašcieņai un pašu dzejas meistaru Kultūras rondo ierakstā no Jāņa Baltvilka atceres sarīkojuma, atzīmējot viņa 80. dzimšanas dienu. Katru vasaru, 24. jūlijā, dzejnieka Jāņa Baltvilka dzimšanas dienā, tiek pasniegtas balvas bērnu un jauniešu literatūrā un grāmatu mākslā. Šogad – dzimšanas diena bija īpaša, jo tā ir astoņdesmitā, tāpēc nākamajā dienā pēc balvu pasniegšanas Jāņa Baltvilka bijušie kolēģi un domubiedri gan ornitoloģijā, gan dzejā, gan bērnu preses izdevumos "Pionieris" un  "Zīlīte", gan grāmatizdošanā sapulcējās uz atmiņu pasākumu Latvijas Nacionālajā bibliotēkā. Visus iespējami koordinētā atmiņu laikā un telpā turēja dzejniece Inese Zandere. Piedalījās Māris Rungulis, Inguna Cepīte, Silvija Tretjakova, ornitologi Māra Janaus, Māra Kazubierne un Oskars Keišs, dabas fotogrāfs, kurš sevi neuzskata par fotogrāfu, Andris Eglītis un māksliniece Anita Paegle. Viss sākās ar, šķiet, Baltvilkam netipisku dzejoli, bet izrādās, ka tas pieder pie tiem nebērnu dzejoļiem, par kuriem parasti nedomājam, sakot Jānis Baltvilks. Prātā vispirms nāk dabas un bērnu dzeja, tāpēc šoreiz atmiņās, protams, būs putni, bērnu dzeja un piedzīvojumi dabā un presē, bet ne tikai. Un interesantāka par pašu dzejoli ir klātesošo bērnu reakcija. Varētu tikai vēlēties, lai atmiņas par Jāni Baltvilku atrastu vietu kādā grāmatā, jo tās būtu arī atmiņas par laiku, iekārtu, veidiem, kā varu varēja apiet un ieelpot svaigu gaisu, piemēram, dabā un bērnu dzejā. Vēl tikai piebilde, ka Jāņa Baltvilka dzimtajās mājās Smārdes pagasta "Zīlītēs" tagad notiek dažādi ar literatūru un dabu saistīti pasākumi, un arī pirmā rakstnieku rezidence. Savukārt līdz līdz 30. septembrim Latvijas Nacionālā bibliotēkā pie Baltā Vilka klases 6. stāvā bibliotēkas darba laikā ir apskatāma Jāņa Baltvilka drauga, dabas fotogrāfa Andra Eglīša, lielformāta fotogrāfijas, kas ļauj ieskatīties dzejnieka pasaulē.

In this special throwback episode, John Hovanesian, MD, and Jim Mazzo revisit their discussions with Steven Schwartz, MD, and Sean Ianculev, MD, about innovations, treatments and entrepreneurship in eye care. Welcome to the Eyeluminaries podcast :10 About Steven Schwartz, MD 2:32 The interview 3:16 Discussion of current innovation in cataract surgery including use of AI, imaging and robotics 4:05 Discussion on Schwartz's involvement in Neurotech MacTel cell-based treatment 6:32 Advances and disappointments in retinal disease treatments? 10:32 How do companies come back from disappointing trial results? 11:07 Why do retina discoveries take so long to develop? 14:31 New dry AMD treatments in development? 15:58  Drug delivery technologies and will retina specialists use them? What do you predict we'll be doing differently in medicine 2 years from now and why? 22:00 What's the difference between a retina and cornea specialist? 23:52 Introduction of Sean Ianchulev, MD, MPH 25:38 The interview 26:29 Impact on Google Glass 30:27 What innovations are you proud of and what projects are you excited about? 35:31 What advice do you have for new entrepreneurs? 42:16 How do you balance your work life and your home life? 45:25 Legends in the field of ophthalmology 47:39 Give feedback at eyeluminaries@healio.com 49:36 Thanks for listening 49:57 Sean Ianchulev, MD, MPH, is a Harvard-trained physician-scientist, a professor of ophthalmology and the head of innovation and technology at New York Eye and Ear Infirmary founder and chairman of Iantrek Inc and Eyenovia and serves as a board member for the American Society of Cataract and Refractive Surgery Foundation and AEYE Health. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. Steven Schwartz, MD, is the Ahmanson professor in ophthalmology and the chief of the retina division at the UCLA Jules Stein Eye Institute and the director of the Diabetic Eye Disease and Retinal Vascular Center. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. You can reach Dr. Schwartz via email at schwartzpatients@jsei.ucla.edu. You can find Dr. Ianchulev on LinkedIn.  Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Schwartz is the co-founder of Horizon Surgical; member on the National Eye Institute Audacious Initiative Scientific executive committee and reports receiving grants from Neurotech, Optos/Nikon, the California Institute of Regenerative Medicine; and investigator fees from Neurotech and Optos/Nikon and the California Institute of Regenerative Medicine.

Alytaus miesto tarybai teikiamas sprendimas dėl Alytaus darželių „Obelėlė“, „Vyturėlis“ bei „Linelis“ tėvų peticijos. Tėvų peticijoje buvo prašoma leisti formuoti po 2 priešmokyklinio ugdymo grupes šiuose darželiuose. Alytaus miesto savivaldybės peticijų komisija, posėdžiavusi rugpjūčio 7 dieną, išnagrinėjo peticiją ir vieno balso persvara priėmė sprendimą siūlyti tarybai tėvų prašymo netenkinti. 5 Peticijų komisijos nariai balsavo už tokį sprendimą, 4 buvo prieš. 

In this episode, we're privileged to have Tom Kosnik, president of the Visus Group, on this weeks Industry Spotlight. In this episode, he delves into the intricate world of compensation plans, sharing best practices for creating detailed, effective, and motivating compensation packages.We'll explore why a well-crafted compensation plan is crucial, not just for attracting top talent but for ensuring a company's professionalism and long-term success. Tom also highlights the importance of earmarking 20-25% of gross profit for employee compensation and warns against pitfalls like overallocation, which can decimate a company's net income.We'll dig into real-world examples, discuss the importance of annual evaluations, and unpack the strategic levers that make a compensation plan both motivating and sustainable. Whether you're a CEO of a staffing or recruiting firm, operations manager, or recruiter, this episode is packed with valuable advice to help you navigate and optimize your compensation strategies. Tune in for all this and more on this episode of The Full Desk Experience!______________________Follow Tom Kosnik on LinkedIn: https://www.linkedin.com/in/tkosnik/Check out the Visus Group Website: https://www.visusgroup.com/Follow Crelate on LinkedIn: https://www.linkedin.com/company/crelate/Subscribe to our newsletter: https://www.crelate.com/blog/full-desk-experience______________________Tom Kosnik, founder and president of the Visus Group is one of the staffing industry's leading experts in organizational design, profitability improvement and work culture transformation. With a commitment to empowering staffing firms with the knowledge and tools to help business owners increase the value of their enterprise asset by helping them grow their business. Tom has coached and consulted hundreds of staffing executives throughout North America using his empirical based “Organizational Development Business Model” (ODBM). Most notably, Tom is the founder of the Presidents RoundTable, a nationwide leadership forum program strategically aimed at helping staffing professionals collaborate and solve industry challenges. With over 25 years of consulting experience in the staffing industry, Tom's diverse array of services have helped numerous staffing firms across the country improve their operations and bottom lines. As a RoundTable facilitator, Tom leads real world business problem-solving sessions in which he advises top executives on a variety of matters, including how to make winning business decisions; achieve profitability benchmarking; and reach peak performance through best practices. To date, he has conducted over thousands of RoundTable forums for all types of staffing professionals, including presidents and CEO's, CFO's, CRO's, and CMO's. Throughout the course of his career, Tom has been a frequent speaker for many world-renowned industry organizations and corporate groups, including the American Staffing Association (Staffing World); National Independent Staffing Association (NISA); Illinois Staffing Association (ISSA); California Staffing Professionals (CSP); Missouri and Kansas Search and Staffing Association (MKSSA); and Massachusetts Staffing Association (MSA). He has presented on a variety of topics, including leadership development; strategic planning for small and large staffing firms; compensation planning; best management techniques; and mergers and acquisitions, among countless other topics. Tom's research and expertise has been published in dozens of national industry publications, including Staffing Industry Review; International Human Resource Management Journal; and Chicago Law Journal, just to name a few. Tom holds an M.A. from Bowling Green State University in Organizational Development and a B.A. in Psychology from Seattle University. In addition, he is certified with the Center for Creative Leadership and a leading sales enhancement organization, MH Group. 

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo chat with Cathleen McCabe, MD, about the ASCRS Foundation and role models in ophthalmology; plus, the latest news in eye care. •    Welcome to the Eyeluminaries podcast :05 •    Review of episode 25 :46 •    Bausch + Lomb acquires Trukera Medical 1:32  •    CMS proposes cutting physician payments for fifth straight year 4:09 •    FDA clears Alcon's Unity cataract system, Unity vitreoretinal cataract system 7:40 •    FDA approves Eylea biosimilar FYB203/Ahzantive 11:07 •    Intro of Cathleen McCabe, MD 13:07 •    American Society of Cataract and Refractive Surgery (ASCRS) has become an important organization to advocate, educate and organize doctors and their practices. As future president of the organization, what vision do you have for the organization? 15:26 •    In reference to your practice, what challenges are you facing and how do you overcome them? 18:59 •    Besides the two of us, who do you admire in ophthalmology? 23:37 •    Tell us about your work, what you do and how you do it. 27:21 •    Preview of episode 27 33:30 •    Thanks 34:58 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Cathleen McCabe, MD, is chief medical officer of Eye Health America and medical director of The Eye Associates in Sarasota, FL. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. McCabe reports no relevant financial disclosures.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo are live from the Octane OTF with Euan Thomson, PhD, Barry Kuppermann, MD, Jeffry Weinhuff, Ehsan Sadri, MD, FACS, and a special announcement from Rich Small. Welcome to the Eyeluminaries podcast :05 Review of episode 24 1:38 Intro of Euan Thomson, PhD 2:10 What kind of companies did you like working for the most? 3:14 Can you comment on why adoption of digital solutions is slow and what we can do about it? 4:15 Geographically speaking, what is the area that is doing the best to incorporate new practices in medicine? 6:04  Can you talk about any real-world evidence of the value of using digital ophthalmic workflows being realized today? 7:51 Intro of Barry Kuppermann, MD, PhD 13:06 Before his passing, you had several years where you worked with one of the most beloved people in ophthalmology, Roger Steinert. What it was like to work with him? Tell us a fun or inspiring story. 15:51 What are the biggest challenges today in resident/fellow education? What advice would you give graduating residents/fellows? 18:05 GHEI has a strong research program. Does it get tougher each year to fund quality research? 20:01 Where do you want to see GHEI in the long-term? 23:55 Intro of Jeffry Weinhuff 26:02 Tell us about your career before entering eye care investing. What is different about our unique specialty within healthcare? 26:38 Tell us about the Visionary Ventures Fund. Is it looking for new physician investors? 30:24 Announcement from Rich Small 34:12 What does Neurotech do? 36:56 Intro of Ehsan Sadri, MD, FACS, FAAO 38:48 Doctors frequently get asked to make investments in start-up companies. How do you decide if an investment is a good one? 42:13 What do you think have been the most innovative companies in eye care during your career? 45:09 Preview of episode 26 49:33 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Barry Kuppermann, MD, PhD, is the Roger F. Steinert professor, chair of the department of ophthalmology and director of the Gavin Herbert Eye Institute at the University of California, Irvine. He also holds a joint appointment with the department of biomedical engineering at UC Irvine. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Ehsan Sadri, MD, FACS, FAAO, is board-certified, fellowship-trained in treating LASIK, cataract and glaucoma surgeries with locations to serve patients in Newport Beach, Santa Ana and Orange. He is also CEO and founder of Visionary Eye Institute and general partner and co-founder of Visionary Ventures Fund (Visionaryvc.com). Rich Small is CEO and member of the board of directors for Neurotech. Euan Thomson, PhD, is the president of ophthalmic devices and head of digital business unit at Carl Zeiss Meditec Inc. Jeffry Weinhuff is the chief investment officer and managing partner of Visionary Ventures Fund, a later-stage venture fund focused on investing in drugs and devices for the eye. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Sadri is the CEO and founder of Visionary Eye Institute and general partner and co-founder of Visionary Ventures Fund. Weinhff is the managing partner of Visionary Ventures Fund. Small is chief executive officer and member of the board of directors for Neurotech. Thomson is the president of ophthalmic devices and head of digital business unit at Carl Zeiss Meditec Inc. Weinhuff is the managing partner of Visionary Ventures Fund.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss leadership in eye care with guest Jack T. Holladay, MD, MSEE, FACS. Brought to you by Johns Hopkins University. •  Welcome to the Eyeluminaries podcast :21 •  Review of episode 23 1:19 •  Blog by John A. Hovanesian, MD, FACS 3:10 •  Merck to acquire EyeBio 4:14 •  FDA approves aflibercept biosimilars Yesafili, Opuviz 6:26 •  Aurion Biotech completes enrollment in phase 1/2 corneal edema cell therapy trial 8:43 •  Intro of Jack Holladay, MD, MSEE 11:10 •  How did you develop a passion for optics? Did you know it was going to be your future? 13:50 •  Holladay's life-threatening situation 16:21 •  Holladay's experience teaching residents 23:50 •  Holladay's optics strategy for improving his golf game 28:33 •  Preview of episode 25 32:25 •  Feedback, questions and guest suggestions at eyeluminaries@healio.com 32:45 Jack T. Holladay, MD, MSEE, FACS, is a clinical professor of ophthalmology at Baylor College of Medicine and retired from clinical ophthalmic practice. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus.

Latvijā šobrīd valda tādi laika apstākļi, ka viss aug griezdamies. Un strauji izplatās arī dažādi augu kaitēkļi. Ko vēl preventīvi var paspēt dārzā izdarīt, lai vēlāk nebūtu jācīnās ar sekām, vaicājam speciālistiem raidījumā Kā labāk dzīvot. Skaidro "trauksmes cēlājs" - Stādu audzētāju biedrības valdes priekšsēdētājs, stādaudzētavas „Dimzas” vadītājs Andrejs Vītoliņš, Valsts augu aizsardzības dienesta Integrētās augu aizsardzības daļas vadītāja Anitra Lestlande un biedrības "Latvijas dārznieks" eksperte Mārīte Gailīte. Dažādu dārza kaitēkļu šajā sezonā tiešām ir daudz, un Andrejs Vītoliņš norāda, ka nopietni ir jāinformē dārzu īpašnieki, kā ar tiem cīnīties. Viņu uztrauc dažādi sadzīviski padomi, kas pieejami sociālajos medijos. Izmantojot ieteiktās metodes un līdzekļus, varbūt arī augus no kaitēkļiem pasargās, bet pastāv iespēja pašiem saindēties. Vadoties pēc dažādiem tautas padomiem var nonākt pie tā, kas visus satrauc, - mēs indējam pasauli. "Vienā rokā mums ir komentāri un sabiedrības viedoklis par to, ka vajadzētu ekoloģiskāk, zaļāk un saudzēt vidi, pretējā pusē ir sabiedrības daļa, kas šausminās, netiek galā ar kaitēkļiem un slimībām un cīnās ar visiem pieejamiem līdzekļiem," komentē Andris Vītoliņš. Anitra Lestlande norāda, ka daudzi amatierdārzkopji vēlas izķert jebkuru kukaini dārzā, nepadomājot, vai tas ir kaitēklis vai labs kukainis. Visu gribas ātri un efektīvi. "Mums ir tāda vīzija izveidojusies, ka ar vienu kaut ko izdarot, uzpūšot kādu brīnumlīdzekli, es tikšu vaļā no problēmām uz visu vasaru. Dabā tā nemēdz būt," skaidro Anitra Lestlande. "Labi zinām, ka atkarībā no laika apstākļiem kaitēkļi mēdz savairoties vai sabremzēties. Ir dažādas nianses, kas tiem, kuri interesējas par augiem, par dārzu, uzliek ne gluži pienākumu, bet vajadzētu tā būt, ka viņi interesējas par kaitēkļu bioloģiju, par augu bioloģiju, kā to ietekmē laika apstākļi." "Bīstams mīts, ka ar ķīmiju var iznīcināt kādu sugu," norāda Mārīte Gailīte. "Sugu var iznīcināt tikai tad, ja tās sugas dzīvotnes vairs nav. Kamēr apstākļi ir labvēlīgi sugas dzīvei, tā būs. Mēs varam tikai aizsargāt savus augus. Iznīcināt sugu - neceriet." Vītoliņš piekrīt, ka nemaz nav arī jāiznīcina, tikai jāsamazina apjoms, vispirms saprotot, cik lielā mērā jācīnās. Viņš mudina vērsties pie padoma pie speciālistiem dārzkopībā, lai gan viņi tiek izslēgti no dažādām sociālo mediju dārzkopju grupām. "Ja par kādu jautājumu atbilde skan: "es domāju, ka vajadzētu tam strādāt tā", ignorējiet," norāda Andrejs Vītoliņš. "Tāpat kā par politiku un viltus ziņām, ir jāmācās filtrēt arī šādas dārzkopības ziņas, kuras korektas, kompetentas. Sliktākajā gadījumā zvaniet, ja nevarat saprast no interneta, audzētavas blakus ir, augu aizsardzības inspektori arī ir pieejams. Publiski lasām mājaslapās kontaktu sadaļas un zvaniet visiem pēc kārtas." 

Klajā nākusi Ilgoņa Vilka monogrāfija "Astronomija Latvijā 20. gadsimtā. 1. daļa". Grāmata veltīta Latvijas astronomijas vēsturei, piedāvājot lasītājam iepazīt ne tikai nozīmīgu astronomu vārdus un dzīves gājumus, bet arī stāsta par astronomisko institūciju likteni sarežģītā gadsimtā. Raidījumā tiekamies ar autoru - Ilgoni Vilku. Nesen raidījumā Zināmais nezināmajā ar astronomu Ilgoni Vilku sarunājāmies par Visumu, tā mērījumiem un vēsturi. Atvadoties pēc šīs sarunas, tapa skaidrs, ka tūlīt, tūlīt dienasgaismu ieraudzīs arī astronoma jaunā grāmata. Tieši tāpēc satiekames atkal, tikai šoreiz nevis Latvijas Radio studijā, bet Latvijas Universitātes ēkā Raiņa bulvārī 19, kur atrodas arī Frīdriha Candera un Latvijas astronomijas kolekcija un kur interesenti var apmeklēt 1869. gadā pabeigto Astronomisko torni, kas kopš pagājušā gadsimta 80. gadiem darbojas kā publiskā observatorija. Šie notikumi ir daļa no Latvijas astronomijas vēstures, un tieši par jauno monogrāfiju “Astronomija Latvijā 20. gadsimtā” (1. daļa) saruna ar monogrāfijas autoru, astronomu, Latvijas Universitātes Astronomijas institūta pētnieku Ilgoni Vilku. "Faktiski kaut kādā mērā vēsturei es biju pievērsies jau diezgan sen. 1986. gadā, kad sāku strādāt šeit, Latvijas Universitātē, tad mans pirmais uzdevums bija savest lietošanas kārtībā tieši šo astronomisko torni, lai tajā atkal darbotos teleskops un cilvēki varētu to apmeklēt. Un, saprotams, ka interesējos arī par torņa vēsturi. Mans tiešais priekšnieks, pats būdams astronomijas vēsturnieks, Leonīds Roze mani rosināja rakstīt žurnālam "Zvaigžņotā Debess", un tā tapa pirmā tāda pavisam vienkārša un neveikla publikācija par astronomijas vēsturi," atminas Ilgonis Vilks. "Atkal pie vēstures tēmas esmu atgriezies pēdējos gados. Jānis Klētnieks, astronoms un ģeodēzists, kurš nu jau ir mūžībā, uzrakstīja grāmatu "Astronomija un ģeodēzija Latvijā līdz 20. gadsimtam". Es viņam teicu - nu tad jāraksta tālāk, viņš teica - nē, lai to raksta pēc manis citi. Tā arī sanācis, ka šobrīd es tā kā esmu vienīgais cilvēks, kurš pārzina to astronomijas vēsturi pietiekami labi, lai varētu mēģināt arī kaut ko rakstīt. Un tā pirms pieciem gadiem iesāku šo grāmatu rakstīt, un tad, kad jau biju aprakstījis pamatā tos notikumus, kas risinājušies Latvijas Universitātē, mazliet arī pirms, par trimdas astronomiem un vēl dažas papildu lietas, tad sapratu, ka ir jau uzrakstījis tik daudz, ka jāsāk domāt par grāmatas dalīšanu uz pusēm. Runāju mūsu universitātes akadēmiskā apgāda darbiniekiem, un atbilde bija - jā, vajag pirmo daļu. Nu, te nu mēs esam!" turpina Ilgonis VIlks. Protams, būs arī otrā daļa. "Būtībā jau pat puse ir uzrakstīta. Plāns jau bija sastādīts pilnībā. Proti, ja šī pirmā daļa vairāk atspoguļo notikumus Latvijas Universitātē, tad otrā daļa galvenokārt būs veltīta notikumiem Latvijas Zinātņu akadēmijā, kur 20. gadsimta vidū izveidojās, sāka darboties astrofizikas observatorija. Par to jāizstāsta. Tur ir daudz cilvēku strādājuši vairākus gadu desmitus. Ir gana daudz aprakstāmo materiālu.  Tāpat Latvijas Astronomijas biedrība, kam agrāk bija garāks nosaukums, tāpat dažādi muzeji Latvijā, kas lielākā vai mazākā mērā saistīti ar astronomiju. Kā notika zinātnes popularizēšana padomju laikos un pēc tam. Mācības: kā, kad un cik skolā mācīja un tagad māca astronomiju. To visu arī vajadzētu iekļaut," vērtē Ilgonis VIlks. Ieskats raķešu zinātnē Pirms runājam par astronomijas vēsturi, ieskatīsimies raķešu zinātnē vārda tiešā nozīmē. Proti, uzzināsim, kā speciālisti aprēķina kosmosa kuģu  trajektoriju, kā var noteikt to, kad, cikos un kur nosēdīsies konkrētais izplatījumā palaistais aparāts. Par to, kā arī par gadījumu, kad aprēķinos tika pieļauta kļūda,  stāsta astronomijas entuziasts Ints Ķešāns. Skatoties no Zemes uz izplatījumu, šķiet, ka daudz vienkāršāk ir palaist raķeti kosmosā, nekā izmanevrēt automašīnu darbadienas pēcpusdienā Rīgas centrā. Taču, lai kosmosa kuģis vai kosmosa izpētes zonde nonāktu konkrētā vietā vai savienotos ar Starptautisko kosmosa staciju, ir nepieciešami ārkārtīgi precīzi aprēķini. Viss sākas ar pirmajām sekundēm, kad raķete tiek palaista orbītā jeb dodas pa noteiktu līniju kosmiskajā telpā. IT speciālists un astronomijas entuziasts Ints Ķešāns palīdz ieviest skaidrību jautājumos saistībā ar kosmosa kuģu trajektorijas noteikšanu. Ints Ķešāns skaidro, ka kosmosa kuģu ceļa aprēķinos tiek izmantoti Ņūtona likumi, gan Krievijas kosmosa teorētiķa Kosntantīna Ciolkovska izstrādātie kosmosa kuģu ātruma vienādojumi. Visus šos aprēķinus jau kopš pagājušā gadsimta vidus, kad sākās kosmosa iekarošana, veic ar elektronikas palīdzību. Mūsdienās aprēķini tiek veikti ar datora palīdzību, pārsvarā visas kosmosa kuģa darbības ir ieprogrammētas, tomēr nevar izslēgt gan aparātu kļūdas, gan cilvēcisko faktoru. Ints Ķešans atsauc atmiņā gadījumu, kad aprēķinu kļūmes dēļ, vairākus simtus miljonu ASV dolāru izmaksājusī Marsa izpētes zonde sadega.  

Lietuvoje pagrindinė Respublikos Prezidento rinkimų ir referendumo dėl Konstitucijos 12 straipsnio pakeitimo diena, kai tikimasi sulaukti didžiausio balsuojančių rinkėjų skaičiaus.Sveikatai palankus poilsio režimas menkai suderinamas su naktiniu darbu, tačiau dalis žmonių dėl darbo specifikos naktį miegoti negali. Naujame „Miego DNR“ epizode neuromokslininkė Laura Bojarskaitė pataria, kaip sumažinti nepastovaus poilsio ritmo daromą žalą organizmui.Kaune veikiančiame klube „Likimo draugai“ kasdien renkasi žmonės, sergantys psichikos ligomis. Čia juos pasitinkanti vadovė Jolanta Stankūnienė visus įtraukia į aktyvias veiklas, moko dirbti socialinėse dirbtuvėse. Daugeliui tai pirmas darbas jų gyvenime.Artėjant 100-mečio Dainų šventei, LRT Klasika pristato ciklą „100 balsų Dainų šventei“. Visus pasakojimus rasite LRT radiotekoje, na, o šiandien susitiksime su choro vadovu ir dirigentu Remigijumi Adomaičiu, kuris po studijų Klaipėdoje, pačioje nepriklausomybės pradžioje atvyko į Šiaulius ir subūrė berniukų ir jaunuolių chorą „Dagilėlis“.Ved. Gabija Narušytė

Tom Kosnik, founder and president of the Visus Group is one of the staffing industry's leading experts in organizational design, profitability improvement and work culture transformation. With a commitment to empowering staffing firms with the knowledge and tools to help business owners increase the value of their enterprise asset by helping them grow their business. […]

Šajā epizodē viens Mārtiņš dalās ar savām iespaidiem no vecāku sapulces, atklājot, kāda bijusi šī tikšanās un kādas tēmas tika apspriestas. Otrs Mārtiņš atgriezās no Itālijas, daloties ar savām piedzīvojumiem un iespaidiem no ceļojuma. Annija savukārt stāsta par savu jauno ceļu uz autopilota - autoskolu, atklājot gan savas bažas, gan priekus šajā jaunajā posmā savā dzīvē. Visus pārsteidza Sahāras putekļu mākonis, kas iepriecināja gan fotogrāfus, gan cilvēkus, kas novēroja dabas fenomenu pār Latviju. over art - https://www.instagram.com/rottwang/ Audio apstrāde - Gatis Gavars Seko mums šeit - https://www.instagram.com/eitanazija/ Pievienojies Facebook grupai - https://www.facebook.com/groups/2705724416375418 Kļūsti par Patronu - https://www.patreon.com/eitanazija

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo chat with Terry Kim, MD, and Stephen Lane about their careers and transitions at Alcon. Brought to you by Johns Hopkins University. Welcome to the Eyeluminaries podcast :21 Review of episode 22 1:27 Intro of Stephen Lane 2:41 Intro of Terry Kim, MD 6:02 Lane: Why retire? What's next? 7:54 Kim: Why the move to the industry? 10:35 Lane: What does a chief medical officer do? What did you learn from the time you went from practice to CMO, and what were some of the surprises? 13:14 Kim: What do you see as some of the challenges you will be facing? 18:19 Lane: What will you miss the most about being a CMO? 21:03 In your experience, how do you navigate transitions in a company and lead without losing focus? 24:22 Preview of episode 24 30:45 Feedback, questions and guest suggestions at eyeluminaries@healio.com 31:34 Thanks for listening 32:08   John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Terry Kim, MD, is a professor of ophthalmology at Duke University Eye Center. Stephen Lane is a founding partner of Associated Eye Care. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news in eye care and chat with Wiley A. Chambers, MD, about his career in the FDA and his plans for retirement. Brought to you by Johns Hopkins University Welcome to the Eyeluminaries podcast :21 Review of episode 21 :50 Clobetasol propionate ophthalmic suspension 0.05% approved for postop inflammation, pain 2:49 PulseSight Therapeutics launches with focus on non-viral gene therapies 5:31 FDA clears first investigational new drug application for neuropathic corneal pain 7:59 APX3330 ‘promising' oral treatment option for slowing progression of diabetic retinopathy 10:20 H. Dunbar Hoskins Jr., decorated glaucoma specialist, dies 11:55 Intro of Wiley A. Chambers, MD 13:36 What are you most proud of accomplishing in your 36 years at the FDA? 15:54 What about oral therapies for the eye? 17:30 What do you wish you could change? 18:46 What advice would you give an innovator with a new drug idea? 21:31 What's next for Wiley Chambers? Ocular Advisors, LLC 23:17 What has changed since you left the FDA? 25:11 Second annual drug name awards: The Year of Vs and Ys 27:04 “Needs to buy a vowel” award 28:49 “i before e” award 30:23 “Most likely to be misspelled” award 31:44 “Is there a way to pay for it?” award 33:17 The cutesy award 34:29 “Need an award” award 36:10 Preview of episode 23 38:17 Feedback, questions and guest suggestions at eyeluminaries@healio.com 39:59 Thanks for listening 39:36 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Wiley A. Chambers, MD, is a clinical professor of ophthalmology and adjunct assistant professor of computer medicine at The George Washington University and owner of Ocular Advisors, LLC. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Chambers is the owner of Ocular Advisors, LLC. Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.

Lai gan Latvijā nav tik izteiktas jauniešu bezdarba problēmas, kā tas ir citās Eiropas valstīs, tomēr jāatzīst, ka zināmas problēmas pastāv, jo vienus darba devēji ķertin izķers, bet citiem būs jāreģistrējas bezdarbniekos. Kāpēc tā, skaidrojam raidījumā Kā labāk dzīvot. Raidījuma viesi: uzņēmuma "ZZ Dats" projektu vadītāja, Rīgas Tehniskās universitātes studente Ilze Zane Radziņa, RTU karjeras konsultante Santa Latkovska un uzņēmuma „Allnex” personāla vadības projektu vadītāja Agija Dzērve. Sazināmies ar Nodarbinātības valsts aģentūras karjeras konsultanti Gunu Sīli. Visus, kuri lūkojas pēc darba vai prakses vietām, ir ieinteresēti karjeras maiņā, Rīgas Tehniskā universitāte (RTU) aicina piedalīties Latvijā lielākajā profesionālās orientācijas pasākumā "Karjeras diena". Tas notiks 8. martā no plkst. 10 līdz 18 Starptautiskajā izstāžu centrā Ķīpsalā, Rīgā. Karjeras dienā piedalīsies vairāk nekā 100 uzņēmumu, notiks "Darba tinderis" un daudz citu aktivitāšu. Šogad "Karjeras diena" notiks 21. reizi. 

Quick episode summary John A. Hovanesian, MD, FACS, and Jim Mazzo sit down with guests Eric D. Donnenfeld, MD, Calvin C. Roberts, MD, Mark L. Baum and Jeannette Bankes to discuss private equity, industry breakthroughs and more. Welcome to the Eyeluminaries podcast :00 Review of episode 20 1:16 Intro of Eric D. Donnenfeld, MD 2:06 Understanding the role of private equity: where does it stand and where is it going? 4:22 Do you see a relief in interest rates and the pace picking up for private equity in the years ahead? 7:19 What are the technologies that you are most excited about? 8:17 What are the things to watch out for? 11:08 Do you have an interesting James Worthy story? 13:34 Intro of Calvin C. Roberts, MD 15:21 Transplanting eyes and Advanced Research Project Agency for Health (ARPA-H) 15:48 How does a chief medical officer work within a company? 18:56 How is what ARPA-H doing different than simply transplanting an eye? 20:42 Intro of Mark L. Baum 26:06 What does the rebranding of the company mean? 27:00 Pharmaceutical names: VEVYE 28:22 How will you market VEVYE in the US? 29:48 Fortisite 31:59 What is the future of the company? 32:47 What do you think of Dr. Wiley Chambers' retirement? 34:09 Intro of Jeannette Bankes 36:51 Describe your last five years in the ophthalmic space: the good, the bad, the ugly 39:16 ·       If you could change anything in the ophthalmic industry, what would it be? 42:53 ·       How excited are you about robotics? 44:06 ·       Tell us about your promotion 44:52 ·       How can we develop a more diverse leadership in ophthalmology? 45:31 Preview of episode 22 48:01 Feedback, questions and guest suggestions at eyeluminaries@healio.com 48:18   Jeannette Bankes is the president and general manager of global surgical franchises for Alcon. Mark L. Baum is the founder, chairman of the board and chief executive officer of Harrow. Eric D. Donnenfeld, MD, is a cornea, laser cataract and refractive surgeon for OCLI Vision. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Calvin C. Roberts, MD, is a program manager for health science futures at ARPA-H. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Bankes is the president and general manager of global surgical franchises for Alcon. Baum is the founder, chairman of the board and chief executive officer of Harrow. Donnenfeld reports consulting widely across the ophthalmic industry with relevant disclosures in this episode as a consultant with Alcon, Bausch + Lomb, LensGen, Ocular Therapeutix and Omeros. Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Thompson is the director of refractive surgery at Vance Thompson Vision. Roberts is program manager for health science futures at ARPA-H.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Vance Thompson, MD, Adrienne Graves, PhD, Sean Ianchulev, MD, and Kristen Harmon Igenito, live from AAO Eyecelerator. Welcome to the Eyeluminaries podcast :01 Review of episode 19 1:31 Intro of Vance Thompson, MD 2:13 What is the secret to your success? 3:54 How many fellows have you trained? 5:20 How has having a fellowship training program at Vance Thompson Vision impacted your practice? 6:23 What are the two recently approved products that you are amazed by? 10:02 What is your favorite wine? 12:55 What is your favorite dad joke? 15:25 Intro of Adrienne Graves, PhD 16:59 How does your background help you serve in the companies and non-profits you work with? 19:43 What do strategics do for companies? 24:13 Prescription drug names 25:53 Intro of Sean Ianchulev, MD, MPH 29:45 How do your ideas evolve? 31:53 ·       Who or what inspires you? 45:58 Intro of Kristen Harmon Ingenito 49:39 How is the software different? 51:45 How is market research changing? 55:19 What are you most optimistic about in terms of trends? The most challenging? 57:18 At what point in your life did you decide to work in market research? 59:05 Preview of episode 21 1:02:32 Feedback, questions and guest suggestions at eyeluminaries@healio.com 1:02:40   Adrienne Graves, PhD, serves as an independent director on the boards of Iveric Bio, Nicox S.A., Greenbrook TMS NeuroHealth, Surface Ophthalmics, Qlaris Bio, and TherOptix and serves as director on the Foundation Boards of the American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology Foundation (Emeritus), Retina Global, Himalayan Cataract Project, and the Foundation Fighting Blindness Retinal Degeneration Fund. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Sean Ianchulev, MD, MPH, is a Harvard-trained physician-scientist, a professor of ophthalmology and the head of innovation and technology at New York Eye and Ear Infirmary founder and chairman of Iantrek Inc and Eyenovia and serves as a board member for the American Society of Cataract and Refractive Surgery Foundation and AEYE Health. Kristen Harmon Ingenito has more than a decade of experience in the ophthalmic industry, with nine of those years analyzing data and reporting for Market Scope. Kristen's industry experience began in 2005 at Market Scope, where she served in many roles, including editing, analysis, sales, and marketing. She then joined an ophthalmic patient education software company, where she worked closely with physicians to help drive value in all aspects of their practices, while also training incoming executives on the business of eye care. She returned to Market Scope with added experience to help expand the company's portfolio of products and services. Source: Market Scope Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Vance Thompson, MD, is a board-certified ophthalmologist who specializes in refractive surgery including laser vision correction, implant vision correction and advanced cataract surgery and is the director of refractive surgery at Vance Thompson Vision. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Graves serves as an independent director on the boards of Iveric Bio, Nicox S.A., Greenbrook TMS NeuroHealth, Surface Ophthalmics, Qlaris Bio, and TherOptix and serves as director on the Foundation Boards of the American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology Foundation (Emeritus), Retina Global, Himalayan Cataract Project, and the Foundation Fighting Blindness Retinal Degeneration Fund. Hovanesian consults widely in the ophthalmic field. Ianchulev is the head of innovation and technology at New York Eye and Ear Infirmary founder and chairman of Iantrek Inc and Eyenovia and serves as a board member for the American Society of Cataract and Refractive Surgery Foundation and AEYE Health. Ingenito develops products and provides services to Market Scope. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Thompson is the director of refractive surgery at Vance Thompson Vision.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Peter Slack, Greg Kunst, Rich Small and Uday Devgan, MD, FACS, FRCS, live from OSN New York. Welcome to the Eyeluminaries podcast :01 Review of episode 18 :18 Intro of Peter Slack 1:47 How did OSN start? 2:35 When did you get into meetings and where do you see meetings going? 5:40 Where do you see media going? 7:46 How did you end up running the Hawaiian Eye Meeting? 10:53 Intro of Greg Kunst 13:59s What will be the biggest challenges introducing a new paradigm for a traditionally surgical disease? 14:52 What can you tell us about Aurion's plans for cell therapy in other front and back of the eye disease, in addition to endothelial cell disease? 17:04 What should I be telling my patients who have future need for endothelial keratoplasty? 19:17 What is the status of Aurion in Japan? Is the competition on the horizon? 22:13 Intro of Rich Small 25:53 Why are you excited about the Encapsulated Cell Therapy Platform? 27:12 Why MacTel? 31:52 What is the status of the Neurotech BLA? 32:26 ·       Give us a good Jim Mazzo story 34:38 Intro of Uday Devgan, MD, FACS, FRCS(Glasg) 37:05 Tell us about how you got started producing one video per day 38:10 Tell us a story about a doctor from far away who is influenced by your teaching 40:38 If you could change one thing in residency training today, what would it be? 41:59 Preview of episode 20 43:51 Feedback, questions and guest suggestions at eyeluminaries@healio.com 44:04   Uday Devgan, MD, FACS, FRCS(Glasg), is Healio|OSN section editor for Ocular Surgery News. He is in private practice, specializing in cataract and refractive surgery, at Devgan Eye Surgery in Los Angeles and a full partner at Specialty Surgical Center in Beverly Hills, California. He has previously served as full clinical Professor of Ophthalmology at the Jules Stein Eye Institute at the UCLA School of Medicine as well as Chief of Ophthalmology at Olive View-UCLA Medical Center and has been actively involved in resident surgical teaching for over two decades. He owns and operates CataractCoach.com. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Greg Kunst is president, chief executive officer and board member at Aurion Biotech. He is focused in areas such as R&D, clinical development, corporate development, strategy, marketing, commercial, business development, market access and medical affairs with extensive knowledge of global health care markets (North America, Latin America, Europe, Asia), global commercialization and market development, upstream and downstream marketing, market access, and medical affairs for medical device, drug delivery systems, diagnostic systems, biotechnology, cell therapies, gene therapies, biologics, and pharmaceutical products. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Peter N. Slack is president and chief executive officer of The Wyanoke Group. Peter is past-Chairman and a current member of the Board of Trustees for the Center for Family Services, a nonprofit human services agency. Other professional titles and memberships have included Board of Directors of the International Association of Association Management Companies and Board of Directors of the American Medical Publishers Association. In addition, Peter is President of the Broadway Theatre of Pitman in Pitman, NJ.  Disclosure: The Wyanoke Group is the holding company for Healio, the producer of the Eyeluminaries podcast. Rich Small is chief executive officer and member of the board of directors for Neurotech. He originally joined Neurotech in July 2007 as the company's chief financial officer. He has in excess of 30 years of both private and public life sciences experience and more than 40 years of overall financial and operational management. Previously Rich served as Senior Vice President and Chief Financial Officer of Point Therapeutics, a publicly traded biotechnology company focused in developing treatments for various cancers. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Devgan owns and operates CataractCoach.com. Hovanesian consults widely in the ophthalmic field. Kunst is president, chief executive officer and board member at Aurion Biotech. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Slack is president and chief executive officer of The Wyanoke Group. Small is chief executive officer and member of the board of directors for Neurotech. The Wyanoke Group is the holding company for Healio, the producer of the Eyeluminaries podcast.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Julia Haller, MD, about the latest developments in retina, residency training and more. Welcome to the Eyeluminaries podcast :01 Review of episode 17, live from Octane OTF :41 Bausch + Lomb makes a number of big moves under the new Brent Saunders regime 1:40 Mark Baum and Harrow Health have also been making a number of acquisitions 3:59 FDA approves Xdemvy for Demodex blepharitis treatment 5:45 Former CEO of Johnson & Johnson Alex Gorsky elected lead director of Neurotech's board 7:47 John begins new clinical committee for ASCRS, digital 9:32 Julia Haller, MD introduction 11:30 ReST Committee update on intraocular inflammation reported in patients who received Syfovre at the American Society of Retina Specialists annual meeting 13:44 The FDA approved Izervay for the treatment of geographic atrophy secondary to age-related macular degeneration, according to a press release from Astellas Pharma 14:16 Novartis is discontinuing the development of GT005 for the treatment of geographic atrophy secondary to dry age-related macular degeneration 14:36 How has the latest retina news affected patients and physicians? 14:53 The development of biosimilars 19:50 Discussion on pricing of products 21:57 The evolution and future of residency programs 23:34 Fun with retina drug names 27:15 Preview of episode 19 at OSN New York 29:46 Feedback, questions and guest suggestions at eyeluminaries@healio.com 30:15 Thanks for listening 30:27 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Julia Haller, MD, is Ophthalmologist-in-Chief and William Tasman, MD Endowed Chair at Wills Eye Hospital and Professor and Chair of Ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University in Philadelphia, PA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Haller reports being on the board of directors at Bristol Myers Squibb, Opthea and Outlook Therapeutics. She is consultant to Aura Biosciences, Bionic Sight, Lowy Medical Research Institute and Regeneron.

Jonas Miklovas, Karolis Tiškevičius ir Augustas Šustriauskas džiaugiasi Lietuvos rinktinės žaidimu, bet neskuba džiaugtis tuo, kas dar laukia. Tikslas pasiektas, bet gal pabandom dar truputį?   Tinklalaidės partneriai: - Pasiruošk gaivinantiems pojūčiams su trimis skirtingais MYNTHON skoniais. MYNTHON - visada pasiruošęs! - Nord VPN. Apsilankykite https://nordvpn.com/basketnews ir dvejų metų planui gaukite keturis papildomus mėnesius. Jei nepatiks - per 30 dienų galite atgauti pinigus. - Nealkoholinis alus „Gubernija”, daugiau informacijos – https://www.facebook.com/Gubernija Temos: Mes tarp aštuonių stipriausių! (0:00); Pagaliau įveikėm kažką rimtesnio (3:17); Tęsinys – sumalti graikai (3:50); Lietuva – tarp pasaulio čempionato staigmenų? (11:30); Dimšos gynyba ir šviesus Rokelio rytojus (14:24); Rinktinė mėgaujasi (23:12); Igno Brazdeikio ramybė (25:58); Kas dabar laukia Lietuvos ir (ne)sąminingos Šuliausko prognozės (28:12); Brolių latvių stebuklai (33:22); Pagarba Kariniauskui (36:37); Nustokim svaigti, bet nenustokim džiaugtis (38:44); Serbų katastrofa su italais, pratrūkęs Šuliauskas ir išeik, Pešičiau (41:29); Žiūrove, paspausk like, kiek galima? (47:52); Ką išdarinėja brolis latvis? (48:48); Koks dabar pasaulio čempionato topas? (51:10); Kokios komandos laimi čempionatus? (56:54); Kur dingsta super žaidėjai? (59:47); O kas nepriklausomi nuo tų tritaškių? (1:02:20); Kuo 2010-ųjų rinktinė vis dar kietesnė už dabartinę? (1:03:34); Visus triuškinantis BasketNews (1:05:50).

#108 – Kino Kults filmas ne tikai skatās, bet par tām arī lasa! Jā, mēs ne mirkli nevaram bez kino, tāpēc tēmas, kas saistītas par un ap to, mēdz ielavīties arī mūsu lasāmsarakstos, un šoreiz padalīsimies ar dažiem ieteikumiem, ko palasīt, ja interesē aizkulišu stāsti un ne tikai! Visus ieteikumus atradīsiet arī paša apraksta beigās, lai tas, kas ieintersē, vēlāk ir vieglāk atrodams. Šajā raidījumā: Miniziņas, jo nekas baigi interesants nav noticis streiku dēļ (00:03:10); Ko mēs esam izlasījuši (00:20:00). Montāža: Toms Cielēns. Minētās grāmatas: "Alien", "Aliens" – Alan Dean Foster "DisneyWar" – James B. Stewart "Down and Dirty Pictures: Miramax, Sundance, and the Rise of Independent Film", "Easy Riders, Raging Bulls" – Peter Biskind "The Greatest Sci-Fi Movies Never Made", "Tales From Development Hell" – David Hughes "The Grip of Film" – Richard Ayoade "The Invention of Hugo Cabret" – Brian Selznick "The Last Action Heroes: The Triumphs, Flops, and Feuds of Hollywood's Kings of Carnage" – Nick de Semlyen "The Men Who Would Be King" – Nicole LaPorte "Nothing Lasts Forever" – Roderick Thorp "Radiance" – Catherynne M. Valente "Rebel Without a Crew" – Robert Rodriguez "Steve Jobs" – Walter Isaacson

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, are live at OCTANe OTS with Mark Leahey, Brent Saunders, Yari Mitchell and Robert Dempsey, discussing their experiences and influence across the ophthalmic space. ·       Welcome to the Eyeluminaries podcast :01 ·       Review of episode 16 with Stephen McLeod, MD :28 ·       Preview of episode 17, live at Octane OTS 1:00 ·       Introduce Mark Leahey, president & CEO for the Medical Device Manufacturers Association 1:23 ·       Challenges in medical device 2:19 ·       Is it possible for the government to reduce regulation of medical devices while still protecting patients? 4:32 ·       What is MDMA doing for sustainability? 6:50 ·       What is one issue that device manufacturers need to implement? 9:04 ·       Introduce Brent Saunders, Chairman and CEO of Bausch + Lomb 12:23 ·       What's different about Bausch + Lomb today that wasn't around when you first worked for the company? 13:27 ·       Tell us about other products at Bausch + Lomb. 19:22 ·       Introducing Yari Mitchell, the president of Y Factor Consulting, Inc. 23:31 ·       What have been the most important changes in the ophthalmic industry over the past couple of years? 24:58 ·       What advice would you give to an early-career person? 26:15 ·       Favorite memories of Jim Mazzo 29:14 ·       Introducing Robert Dempsey, CEO and President of AsclepiX Therapeutics 32:10 ·       What was it like to leap from medical sciences to a leadership position? 33:22 ·       Managing a pipeline that includes both retinal and cornea treatments 35:05 ·       How do you establish yourself as a competitor in age-related macular degeneration research in a mature and crowded market with limited resources? 36:10 ·       Creating a retinal treatment delivered via the suprachoroidal route 37:28 ·       The Holland Foundation For Sight Restoration seeking to spread access to eye care for patients and the importance of giving back 38:27 ·       Feedback, questions and guest suggestions at eyeluminaries@healio.com 44:00 ·       Thanks for listening 44:19 Robert Dempsey is the CEO and president of AsclepiX Therapeutics. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Mark Leahey is the president and CEO of the Medical Device Manufacturers Association. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Yari Mitchell is the president of Y Factor Consulting, Inc. Brent Saunders is the chairman and CEO of Bausch + Lomb. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Dempsey is the president and CEO of AsclepiX Therapeutics. Hovanesian consults widely in the ophthalmic field. Leahey is the president & CEO for the Medical Device Manufacturers Association. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Mitchell is the chief business development officer at AcuFocus and the president of Y Factor Consulting, Inc. Saunders is the chairman and CEO of Bausch + Lomb.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Stephen McLeod, MD, about his new position and the future of the American Academy of Ophthalmology. ·       Welcome to the Eyeluminaries podcast :01 ·       Review of episode 15, live from Eyecelerator :37 ·       Preview of episode 17, live at Octane OTF 1:07s ·       Théa to acquire seven branded ophthalmic products from Akorn 2:17 ·       FDA approves Miebo to treat signs, symptoms of dry eye disease 5:11 ·       OCS-01 eye drops meet primary, secondary endpoints in diabetic macular edema phase 3 trial 8:56 ·       ‘One of my greatest honors': Jim Mazzo awarded Ellis Island Medal of Honor 10:38 ·       Introduction Stephen McLeod, MD 12:14 ·       What's been your biggest challenge transitioning from clinical practice to your current position? 14:16 ·       Where is the AAO going now? 17:50 ·       Prior authorizations are the bane of operational existence. What is AAOs role in reforming this system? 22:59 ·       The future of meetings 30:27 ·       Preview of episode 17 35:44 ·       Feedback, questions and guest suggestions at eyeluminaries@healio.com 36:47 ·       Thanks for listening 54:02 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Stephen McLeod, MD, is the CEO of the American Academy of Ophthalmology. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. McLeod is the CEO of the American Academy of Ophthalmology.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, are live at the Eyecelerator 2023 with five special guests to discuss the future and developments in eye care. ·       Welcome to the Eyeluminaries podcast :00 ·       Preview of episode 15 :32 ·       Review of episode 14, STAAR Surgical :40 ·       Nick Curtis, CEO of Lensar 1:41 ·       Lensar is a unique company with loyal customers. How have you achieved that? 3:21 ·       What are the positives and challenges to not having a large organization as support? 4:09 ·       Where do you see the company and its products evolving over the next 5 years? 8:01 ·       Do you think the company is going to grow because you are taking share? Or because you are taking share and the market is going to grow? 10:06 ·       What is the accelerator for market growth? 10:19 ·       Who's your favorite Chicago team? 12:03 ·       Juliet Bakker, managing director and founder of Longitude Capital 13:11 ·       What makes ophthalmology an appealing specialty to you from an investment and a personal perspective? 14:30 ·       Give a sense of how you see Eyecelerator as an investor. 18:32 ·       What did you learn from failed investments? 21:39 ·       What are the signs of success that you look for? 23:03 ·       Ramin Valian, vice president Eye Care Allergan/AbbVie 24:31 ·       What is happening in ophthalmology at AbbVie? 25:21 ·       What were the key learnings after launching Vuity? 27:52 ·       Does ophthalmology have the same momentum as aesthetics? 30:12 ·       Susan Siw Daniels, PhD, chief scientific officer at Avellino Labs 34:11 ·       Why is your background perfect for Avellino? 35:06 ·       What things did you see transform in other specialties that you see potentially happening in ophthalmology? 38:02 ·       What data are you looking for to expand predictive testing and treatments in eye care in the future? 39:07 ·       How do you get ophthalmologists more involved in genetic testing? 40:30 ·       Julie Schallhorn, MD, MS 43:00 ·       What's new at the Eyecelerator? 44:42 ·       What are the signs of success in a startup company? 47:44 ·       What is your advice for people who want to balance their time with a medical career and personal life? 49:45 ·       Preview of episode 16 53:28 ·       Feedback, questions and guest suggestions at eyeluminaries@healio.com 53:56 ·       Thanks for listening 54:02 Juliet Bakker is a managing director and founder of Longitude Capital. Nick Curtis is chief executive officer and member of the board of directors at Lensar. Susan Siw Daniels, PhD, is the chief scientific officer at Avellino. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Julie Schallhorn, MD, MS, is an assistant professor of ophthalmology at UCSF. Ramin Valian is the vice president of Eye Care Allergan/AbbVie. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Bakker serves on the boards of Ceribell, Engogenex, Nalu Medical and RxSight. Curtis is a member of the board of directors for Lensar. Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Schallhorn sits on the Ophthalmic Technology Assessment Committee for Refractive Surgery for the American Academy of Ophthalmolgy and the Young Eye Surgeons Committee for the American Society of Cataract and Refractive Surgeons.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the Silicon Valley Bank collapse and its impact on investing and innovation in the field of ophthalmology with Gilbert H. Kliman, MD. ·       Welcome to the Eyeluminaries podcast :01 ·       Review of episode 12 with Richard L. Lindstrom, MD :30 ·       Preview of episode 13 1:35 ·       Gil Kliman, MD, introduction 2:36 ·       History of Silicon Valley Bank 4:25 ·       Silicon Valley Bank's collapse 6:08 ·       Guest welcome 8:07 ·       Was the collapse a surprise? 8:22 ·       Kliman on major themes of this event being how fast it happened and how unprecedented it was for companies 9:34 ·       How many ophthalmic companies have been affected, and what are the next steps for these companies? 10:16 ·       Kliman on the turning point when the FDIC stepped in on Sunday 11:50 ·       Have you had companies report that they have accessed their funds at Silicon Valley Bank? 12:27 ·       Kliman on his experience with Silicon Valley Bank 12:45 ·       What should companies do going forward, and what are you advising companies? 14:17 ·       Kliman on figuring out a new strategy and the unique issue of 90% of depositors being above the $250,000 FDIC threshold 16:13 ·       What is the survival rate for small banks now? 17:31 ·       What do you think the flavor of the room will be at Eyecelerator@ASCRS? 19:20 ·       Kliman's advice for companies to focus on burn rates 20:35 ·       The physician's perspective for supporting innovation and small business 21:54 ·       How strategics can continue to partner with startups using their venture arm 24:04 ·       Information on the Eyecelerator meeting 25:46 ·       Wrap up and thank you, Gil 26:16 ·       Feedback, questions and guest suggestions at eyeluminaries@healio.com 26:45 ·       Thanks for listening, and preview of episode 14 27:11 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Gil Kliman, MD, is managing partner at InterWest Partners and is co-founder and program director of Eyecelerator. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Kliman is managing partner at InterWest Partners.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Richard L. Lindstrom, MD, about the latest news and trends, as well as his career and his advice for residents and entrepreneurs in the field of ophthalmology.        Welcome to the Eyeluminaries podcast :00        OTF Meeting 01:41        Gezundheit award – Iheezo (chloroprocaine hydrochloride ophthalmic gel) 4:04        Name stolen from a birthday party magician award – Vabysmo (faricimab-svoa) 4:42        The incomplete sentence award – Iyuzeh (latanoprost ophthalmic solution) 5:21        Big improvement on the generic name award – Zimura (avacincaptad pegol) 6:24        Best of the year award – Pegcetacoplan 6:49        Near miss award – Beovu (brolucizumab) 8:08        Awful award – Byooviz (ranibizumab-nuna) 8:45        Guest welcome 9:40        Richard L. Lindstrom, MD, introduction 10:31        FDA grants fast track designation for retinitis pigmentosa treatment 10:36        EyeArt AI system approved in EU for detecting AMD, glaucomatous optic nerve damage 13:14        Amazon launches discount prescription drug service 17:46        Interview with Lindstrom 21:42        What is the biggest innovation in ophthalmology in your career? 22:40        What is coming in the next 10 years? 25:24        What is out there that will get in the way of innovation? 26:54        What advice would you give to residents? 28:35        What advice would you give to entrepreneurs? 30:16        What story can you share about one historical figure in ophthalmology? 31:59        Wrap up and a preview of episode 13, guest David Endicot, Alcon CEO 35:14        Feedback, questions and guest suggestions at eyeluminaries@healio.com 36:29        Thanks for listening 36:53 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. Richard L. Lindstrom, MD, is the founder and an Attending Surgeon at Minnesota Eye Consultants and an Adjunct Professor Emeritus at the University of Minnesota, Department of Ophthalmology. He is a board-certified Ophthalmologist and an internationally recognized leader in corneal, cataract, refractive and laser surgery. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Lindstrom reports consulting with AcuFocus, Alcon, Allergan, Bausch + Lomb, Combangio, CorneaGen, Equinox, Eyevance/Santen, Flying L Partners, Harrow Health, J&J Vision, Lensar, Lentechs, MDbackline, Novartis, Orasis, Schroeder Vision Life Sciences, Sun, Surface, Versant Ventures, Visionary Ventures and Zeiss; holds stocks with Acquea, AcuFocus, Combangio, CorneaGen, Equinox, Flying L Investments, ForSight, Harrow Health, Lensar, Lentechs, MDbackline, Ocular Therapeutix, Orasis, Sight4All, Surface, TearClear, TearLab, TherOptix, Unifeye Vision Partners and Visionary Ventures; board chairman of Surface; sits on the board of Acquea, AcuFocus, Combangio, CorneaGen, Equinox, ForSight, Harrow Health, Lensar, Lentechs, MDbackline, Ocular Therapeutix, Sight4All, TearLab, TherOptix and Unifeye Vision Partners; board observer of TearClear; receives compensation from Ocular Therapeutix; member of the investment committee of Flying L Investments and Visionary Ventures; and a medical advisory board member of Acquea, Foresight, Harrow Health, Ocular Therapeutix, Sight4All, TearClear and TearLab.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest news stories, live from Hawaiian Eye. Welcome to the Eyeluminaries podcast :01 Review of episode 10, the Allergan alumni guests 1:30 Bausch + Lomb announces acquisition of AcuFocus 3:39 Mazzo attributes success to people and the magic of ophthalmology 5:40 Keranova's PhotoEmulsification technique shows promising results 9:25 Centricity CEO discusses latest cataract surgery products 11:04 Orasis submits new drug application for presbyopia drop 12:30 Aldeyra submits NDA for primary vitreoretinal lymphoma treatment 15:27 Iveric Bio submits final part of Zimura new drug application for rolling review 17:30 Tom Frinzi to become CEO of STAAR Surgical 22:37 Wrap up and a preview of episode 12 25:38 Feedback, questions and guest suggestions at eyeluminaries@healio.com 27:39 Thanks for listening 28:00 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.